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ABSTRACT OF THE DISSERTATION
Mechanism of Chimeric Vaccine Mediated Immune Suppression of Human Dendritic
Cells
by
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Dr. William Langridge, Chairperson

Type 1 diabetes mellitus is a chronic inflammatory disease in which insulin
producing β-cells of the pancreatic islets are killed by autoreactive cells of the immune
system in response to a loss of tolerance. Dendritic cells (DC) interact predominantly
with naïve T cells to regulate the delicate balance between immunity and tolerance
required to maintain immunological homeostasis. In this dissertation, immature human
dendritic cells (iDC) were inoculated with a chimeric fusion protein vaccine containing
the pancreatic β-cell auto-antigen proinsulin linked to a mucosal adjuvant the cholera
toxin B subunit (CTB-INS). Proteomic analysis of vaccine inoculated DCs revealed
strong up-regulation of the tryptophan catabolic enzyme indoleamine 2, 3-dioxygenase
(IDO1) shown to be directly linked to CTB-INS-induced DC activation and maturation.
Treatment of vaccinated DCs with the pharmacological NF-κB inhibitors ACHP or
DHMEQ inhibited IDO1 biosynthesis, suggesting a role for NF-κB signaling in CTBINS vaccine up-regulation of dendritic cell IDO1. Further, blocking the NF-κB-inducing
kinase (NIK) phosphorylation of IKK-α dimers and translocation of p52/RelB complexes
to the nucleus with anti-NIK siRNA, significantly inhibited IDO1 expression in human
DCs. Chromatin immunoprecipitation (ChIP) analysis, showed that RelB-p52 dimers

xv

bound dendritic cell NF-κB consensus sequences in the IDO1 promoter region,
demonstrating vaccine stimulation of NF-κB non-canonical pathway activation of IDO1
expression in human DCs in vivo. Addition of the Tumor Necrosis Factor Associated
Factors (TRAF) TRAF6 and TRAF 2, 3 blocking peptides to vaccinated DCs
dramatically reduced the level of IDO1 biosynthesis and stimulated DC suggesting the
vaccine may function in the same signaling pathway as TNFR super-family for the upregulation of IDO1 biosynthesis in vaccinated dendritic cells. Together, these data
confirm CTB-INS vaccine activation of the non-canonical NF-κB signaling pathway
TNFR receptor family up-regulation of dendritic cell IDO1 biosynthesis permitting
vaccine inhibition of DC maturation leading to the suppression of type 1 diabetes
development.
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CHAPTER ONE
INTRODUCTION

The Role of Dendritic Cells in Tissue-Specific Autoimmunity
Tissue specific autoimmunity may be defined as a progressive inflammatory
immune response to specific proteins originating from cells in a tissue or organ resulting
in diminished organ function or organ failure. Organ destruction is currently thought to
arise from dysregulation of the immune system. The identification of immune cells
responsible for initiation of autoimmunity remained elusive until a new class of immune
cells, dendritic cells (DC), was discovered in the early 1970’s by Nobel Laureate Ralph
Steinman. Until this time, cells representing the innate and adaptive arms of the immune
system were considered to be separate entities. However, Steinman’s discovery that
dendritic cells were the “missing link” responsible for coordinating innate and adaptive
immune responses has revolutionized the relationship between these two segments of the
immune system. In addition, this discovery allowed the proliferation of many novel
therapeutic strategies for prevention and treatment of tissue specific autoimmunity. The
first clues to interactions between innate immunity and the adaptive immune response
became apparent in 1973 when Steinman and Zan detected the presence of an unusual
immune cell type while observing cells from mouse spleen by phase contrast microscopy
(Steinman & Cohn, 1973, 1974). The authors identified a specific population of immune
cells that did not display the typical morphology of macrophages and which possessed
long “dendrite like” cytoplasmic processes capable of dynamic extension or retraction.
Dendritic cells are the primary line of immune cell defense against pathogens and toxins
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that invade the body. Representing the innate portion of the immune system, dendritic
cells recognize and destroy invading bacterial, viral, protozoan, fungal pathogens and
other foreign molecules that escape the body’s passive defenses. In innate immunity,
monocytes recruited into inflammatory sites differentiate into dendritic cells under the
influence of Th1 cytokines (De Trez et al., 2009). The dendritic cell response comprises
secretion of TNF-α and NO to aid in the clearing of pathogens (Serbina, Salazar-Mather,
Biron, Kuziel, & Pamer, 2003). The inflammatory cytokine TNF-α can bind to receptors
on gram negative bacteria facilitating phagocytosis by macrophages (Luo, Niesel,
Shaban, Grimm, & Klimpel, 1993). Dendritic cells may also activate NK cells through
both contact dependent and contact independent mechanisms (Barreira da Silva & Munz,
2011). When the pathogen load becomes excessive, dendritic cells act primarily as
antigen presenting cells by migrating to the spleen or peripheral lymph nodes and
delivering portions of the invading pathogens to lymphocytes of the adaptive immune
system to amplify the immune response.
An increased awareness of the intricate relationship between dendritic cells and
other cells of the adaptive immune system will be essential for understanding how
immunological homeostasis is achieved and maintained. Further improvements in
understanding how dendritic cells generate peripheral and central tolerance will be
needed before more effective and safer therapeutic strategies can be constructed to
prevent or reverse the process of autoimmunity. In central tolerance, dendritic cells
residing in the thymus present antigens on MHCII and cross present self-antigens on
MHCI receptors to bone marrow derived T cells to stimulate apoptosis of potentially
autoreactive T cells (negative selection) (Gallegos & Bevan, 2004; Hubert et al., 2011).
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Dendritic Cells Origins and Functions
In order to efficiently encounter, process, and transport foreign antigens to lymph
nodes for presentation to T cells, a variety of dendritic cell subsets exist that are
specialized in morphology, function and location (Belz & Nutt, 2012). Dendritic cells,
like most cells of the immune system, comprise a number of groups or subsets that are
distinct either in origin, function, or both. Although classification of DC subsets may
vary, there are four major categories of dendritic cells currently recognized: (1)
conventional dendritic cells (cDCs), (2) Langerhans cells, (3) plasmacytoid dendritic cells
(pDCs) and (4) monocyte-derived dendritic cells (moDCs). Due to differences in
phenotype, an alternative subset of dendritic cells, the myeloid DCs (mDCs) are also
included. The myeloid DC subset consists of both cDCs and moDCs.
Dendritic cell hematopoiesis was originally established in mice and the
corresponding DC subsets were identified in humans. The origin of dendritic cells begins
in the bone marrow with CD34+FLT3+ common myeloid progenitor (CMP) cells
(Brasel, De Smedt, Smith, & Maliszewski, 2000). The CMPs differentiate into restricted
macrophage dendritic cell progenitors (MDP). The MDPs branch to create two separate
dendritic cells lineages: the monocyte and the common dendritic cell progenitor (CDP)
(Belz & Nutt, 2012). Monocytes circulate in the periphery and during inflammation,
differentiate into CD11c+, CD11b+ and MHCII+ moDCs (Cheong et al., 2010). The
CDPs differentiate in the bone marrow into plasmacytoid DCs and into pre-DCs which
give rise to conventional DCs in peripheral tissues (Belz & Nutt, 2012). The only
dendritic cells that do not originate in the bone marrow are the Langerhans cells. The
Langerhans subset is derived from a local Ly6C+ myelomonocytic precursor in the skin
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that originates from macrophages during early embryonic development (Chorro et al.,
2009). Petvises and O'Neill have given a complete review of dendritic cell hematopoiesis
(Petvises & O'Neill, 2012).
Conventional dendritic cells are a highly specialized DC subset that is efficient in
antigen processing and presentation. This major group of dendritic cells can be
categorized as either migratory or lymphoid tissue resident DCs. Migratory dendritic cells
develop from precursors in both lymphoid and non-lymphoid tissues, but are not found in
the spleen (K. Liu & Nussenzweig, 2010). After taking up and processing antigens from
resident tissues, cDCs migrate to the peripheral draining lymph nodes via afferent lymph
vessels to present sequestered antigens to naïve T cells. The migration of cDCs is
markedly amplified during inflammatory conditions. In contrast, lymphoid tissue resident
dendritic cells are located in the spleen, thymus, and lymph nodes. In comparison with
the migratory DC subset, lymphoid tissue resident dendritic cells do not migrate, but
rather develop from dendritic cell precursors already residing in lymphoid tissues (Naik
et al., 2006). During immunological homeostasis, cDCs remain immature, have high
endocytic capacity and synthesize low levels of MHC relative to other dendritic cell
subsets (Shortman & Naik, 2007). Due to their predominant location in the spleen,
lymphoid tissue resident dendritic cells are well suited to sample antigens transported by
the blood. Langerhans cells function in a manner similar to migratory conventional DCs.
They reside in the skin and can be identified by the expression of the
monocyte/macrophage and endothelial cell differentiation antigen Ly6C (Leon, LopezBravo, & Ardavin, 2007). Their function is to capture, identify and present antigens from
the external environment to naïve T cells. Both cDCs and Langerhans cells are necessary
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for the maintenance of immunological homeostasis, with their major functions occurring
during the steady state.
Plasmacytoid dendritic cells arise from lymphoid progenitors and are broadly
distributed throughout the body. In humans, this DC subset can be identified through
expression of immunoglobulin-like transcript 7 (ILT7) and CD45R (Reizis, Bunin,
Ghosh, Lewis, & Sisirak, 2011). Plasmacytoid dendritic cells are generally quiescent but
when stimulated, secrete large amounts of type 1 interferons which induce anti-viral
responses in other immune cells (Trinchieri, Santoli, Dee, & Knowles, 1978).
Plasmacytoid dendritic cells preferentially express intracellular TLRs including TLR7
and TLR9. These toll-like receptors bind pathogen nucleic acids, especially motifs rich in
CpG, and play a major role in pDCs response to viral infections (Hubert, Voisine,
Louvet, Heslan, & Josien, 2004). Because pDCs have low antigen presentation
capabilities, their role in promoting adaptive immunity remains relatively unclear (Reizis,
Colonna, Trinchieri, Barrat, & Gilliet, 2011). However, pDCs are known to play a major
role during inflammation as opposed to cDCs which are more involved in the
maintenance of immunological homeostasis.
Monocyte-derived dendritic cells arise from myeloid progenitors and are crucial
for immune responses because they provide a pool of antigen presenting cells that can
effectively initiate an adaptive immune response following the onset of infection. During
inflammation, it is well known that circulating monocytes express receptors for GM-CSF,
M-CSF, IL-4, and other differentiation and chemo-attractant molecules that recruit them
to the site of inflammation and differentiate them into moDCs. Monocyte derived
dendritic cells are highly potent in antigen processing, presentation, and cross
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presentation (Cheong et al., 2010). They are CD11c positive and express high levels of
MHC II in comparison with other DC subsets. The function of moDCs is similar to cDCs
because they both process foreign antigens from tissues and migrate to the nearest
draining lymph nodes where they present the antigens to naïve T cells. Upon activation,
the lifespan of all DC subsets is relatively similar, as opposed to the length of time DCs
reside in tissue during their immature state (Kamath, Henri, Battye, Tough, & Shortman,
2002).The major responsibility of moDCs and pDCs is to incite an adaptive immune
response through activation of T cells that can resolve inflammation, and return the
immune system to immunological homeostasis. The interaction of moDCs and pDCs with
autoreactive T cells can either induce autoimmune dysfunction or initiate tolerance.

The Role of Dendritic Cells in Autoimmunity
Dendritic cells have well defined roles in both innate and adaptive immunity.
However, it is their ability to link the innate and adaptive immune system that confers
them a role in autoimmunity. In adaptive immunity, DC-secreted factors affect IgA
production by B cells (Tezuka et al., 2007). Most importantly, DCs transfer innate signals
to the adaptive immune system by priming naïve T cells, by stimulating Th1, Th2, and
Th17 responses, by cross presentation of antigens to CD8+ T cells, and by regulating T
cell differentiation (Nakano et al., 2009; Segura, Albiston, Wicks, Chai, & Villadangos,
2009; Yamane & Paul, 2013; Zhu, Yamane, & Paul, 2010). The breakdown of dendritic
cell functions is considered to be the driving force behind the onset of tissue specific
autoimmunity.
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Dendritic cell subsets differ in their specialized functions, including the location
of activity, cytokine profiles, types of antigens detected, migratory or tissue resident
status and presence during immunological homeostasis or during inflammation.
However, the common function of these dendritic cell subsets is the communication of
inflammatory or immunosuppressive signals among the innate and adaptive cells of the
immune system. This function requires two main steps. The first is the identification of
antigens. The second step is the presentation of antigens along with the appropriate
secondary signals required to induce an adaptive T cell response. Dendritic cells identify
antigen via pathogen associated molecular patterns (PAMPS) or damage associated
molecular patterns (DAMPs). As an exogenous signal to dendritic cells for infection,
PAMPs are comprised of molecules common to a variety of organisms but absent in the
host. For example, viral envelope proteins and ssDNA from viruses, lipopolysaccharide
and flagellin from bacteria, zymosan from fungus, and profilin from toxoplasma gondi
are PAMPs which are recognized by specific receptors on dendritic cells. In comparison,
DAMPs are endogenous signals from within cells. Release of ATP, DNA, or uric acid
can be a warning sign to dendritic cells for stress, microbial invasion, or necrotic cell
death such as in the case of cancer (Tang, Kang, Coyne, Zeh, & Lotze, 2012). Dendritic
cells detect PAMPS and DAMPs through several classes of surface and intracellular
receptors called pattern recognition receptors (PRRs). These classes include the receptor
for advanced glycation end products (RAGE), RIG-I-like receptors (RLRs), NOD-like
receptors (NLRs), and Toll-like receptors (TLRs).
Once a dendritic cell has encountered an antigen, it processes and transfers this
information to T cells. Mature DCs interact with T cells through: 1) dendritic cell MHC-
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II/antigen complex interactions with the T cell receptor, 2) dendritic cell CD86/CD80 costimulation of T cell CD28, and 3) dendritic cell cytokine signaling to T cells. Because
the extent of DC activation determines whether interaction with a T cell will induce
tolerance or immunity, antigen presentation in the presence of inflammatory signals
results in immunity while Ag presentation during the steady state results in tolerance
(Probst, Lagnel, Kollias, & van den Broek, 2003). During inflammation, dendritic cells
can induce naïve T cell (Th0) differentiation or activate memory T cells. Upon dendritic
cell maturation, naïve CD4 T cells can differentiate into memory and Th1, Th2, and Th17
effector cells associated with autoimmunity. Naïve CD8 T cells differentiate into
cytotoxic T lymphocytes and CD8 memory cells. During immunological homeostasis,
DC interaction with T cells generates and maintains a population of Tregs. Under
conditions of autoimmunity, autoantigens which should induce tolerance during
homeostasis generate an inflammatory response. In general, the role of DCs during the
development of autoimmunity is to induce autoreactive CD4+ and CD8+ proinflammatory T cell differentiation rather than immunosuppressive Treg development or
autoreactive T cell anergy.
Dendritic cells play a critical role in both the prevention and onset of autoimmune
responses. In the non-diseased state, DCs are responsible for the induction and
maintenance of tolerance towards self-antigens. The induction of T cell tolerance is
dependent on whether a DC is tolerogenic or immunogenic during autoantigen
presentation, and also on the contribution of autoreactive T cells that may escape from
the thymus. Although the continuously developing T cell repertoire is rigorously screened
to develop central tolerance in the thymus, autoreactive T cells which may escape
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apoptosis in the thymus are poised to induce autoimmunity unless regulated by dendritic
cells in the periphery (Kyewski & Klein, 2006). Normally, presentation of a self-antigen
to an autoreactive T cell results in T cell anergy, deletion, activation or induction of Treg
cells (Mayer, Berod, & Sparwasser, 2012).
There are several factors that influence whether a DC will induce tolerance when
presenting self-antigens including but not limited to activation state and method of
antigen capture/antigen source. The activation state of a DC is crucial to the fate of the T
cells with which it interacts. Typically, tolerogenic DCs express low levels of costimulatory molecules (CD80, CD86), generate increased secretion of IL-10 and TGF-β,
and reduced secretion of pro-inflammatory IL-12, IL-1, IL-6, and TNF cytokines. In
addition to these hallmarks of tolerogenic DCs, the secretion of IL-2, and a variety of
enzymes such as retinaldehyde dehydrogenase-2 and indolamine 2, 3-dioxygenase are
involved in the suppression of Th1 mediated autoimmunity in addition to the induction of
Treg cells (Maldonado & von Andrian, 2010; Mayer et al., 2012; Pallotta et al., 2011).
All of these factors are in place to ensure a tolerogenic phenotype in DCs during
presentation of self-antigens. However, these mechanisms to prevent the human immune
system from recognizing self-antigens may occasionally malfunction. In general, this
malfunction can involve self-antigen presentation in the presence of danger signals,
therefore breaking tolerance. For each autoimmune disease, different mechanisms for DC
initiation of autoimmunity are suggested, nonetheless they still remain unclear. For
example, in the case of type 1 diabetes, genetic abnormalities in DC subsets and viral
infection have been linked as initiators of autoimmunity (Morel, 2013). NOD mice have
increased CD11b+ cDCs which have been demonstrated to be responsible for the
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presentation of type 1 diabetes autoantigens to autoreactive T cells (Saxena, Ondr,
Magnusen, Munn, & Katz, 2007b; Steptoe, Ritchie, & Harrison, 2002). In the diseased
state, these cDCs cross-present islet antigens to autoreactive CD8 T cells and secrete
increased IL-12, TNFα, and IL-1 (Morel, 2013). The breach of tolerance induced by
cDCs is speculated to be regulated by pDCs. In some cases, certain viral tropisms induce
the secretion of type 1 inteferons by binding TLRs within pDCs. A localized type 1
interferon response within the pancreas can activate autoreactive T cells and act as a
danger/maturation signal to resident cDCs, therefore promoting presentation of steady
state antigen but in a pro-inflammatory context (Swiecki, McCartney, Wang, & Colonna,
2011). This immunogenic presentation of islet autoantigens to CD8 T cells, may allow
for the homing of cytotoxic T cells to the islets, destruction of the target cells, and the
perpetuation of autoimmunity.

Dendritic Cell Stimulation of Tissue Specific Autoimmunity
Tissue specific autoimmunity requires the release of specific autoantigens
characteristic of a given tissue or organ that can be recognized by dendritic cell PRRs.
Prototypical tissue specific autoimmune disease examples presented in this review are
type 1 diabetes (T1D) and multiple sclerosis (MS), and for comparison examples of
systemic autoimmune diseases discussed are rheumatoid arthritis (RA) and systemic
lupus erythematosus (SLE). The pancreatic β cell, is one of the most specialized cells in
the body and is central to type 1 diabetes onset. In addition to the production, storage, and
secretion of the peptide hormone insulin, the β cell is capable of sensing and responding
to changes in blood glucose levels (Roep & Peakman, 2012). During the earliest stages of
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T1D research, specific islet autoantigens signaling diabetes onset were discovered
through their recognition by islet cell autoantibodies (ICAs). Since identification of ICAs
in 1976, their β-cell protein targets were only slowly revealed (Bottazzo, FlorinChristensen, & Doniach, 1974; Roep & Peakman, 2012). With the exception of insulin
as an obvious T1D candidate autoantigen, it was not until 1990 that the 64 kDa glutamic
acid decarboxylase (GAD) protein was discovered to be an important secondary antigen
for T1D development (Baekkeskov et al., 1990; Roep & Peakman, 2012).
Multiple sclerosis (MS) is a devastating inflammatory disease of the brain and
spinal cord resulting from autoimmune attack against antigens in the central nervous
system (Lutterotti et al., 2013). Pro-inflammatory T cell responses to the major myelin
proteins, myelin basic protein (MBP) and proteolipid protein (PLP), are considered to be
important for the development of MS (Kerlero de Rosbo et al., 1993). However, DCmediated autoimmune responses to other minor myelin antigens such as myelinassociated glycoprotein (MAG) and myelin oligodendrocyte glycoprotein (MOG) may
also play a significant role in disease initiation or progression (Kerlero de Rosbo et al.,
1993).
Unlike organ specific autoimmune diseases, a major challenge exists in finding
individual representative antigens for initiating the onset of systemic autoimmunity
(Figure 1). This difficulty is based on observations by many investigators that the onset
of systemic autoimmunity may be initiated at different times and locations in the
connective tissues of rheumatoid arthritis (RA) and Systemic Lupus Erythematosus
(SLE) patients. Further, the problem of progressive antigen spreading can further
complicate this issue. In confirmation that tissue specificity underlies systemic
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autoimmunity, it was recently shown that hyper-activation of MyD88-adapter dependent
signaling in DCs is sufficient to drive pathogenesis of lupus-like autoimmunity
(Lamagna, Scapini, van Ziffle, DeFranco, & Lowell, 2013). This result emphasizes that
dysregulation of dendritic cells alone can lead to autoimmunity.
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Figure 1. Characteristics of tissue specific and systemic autoimmune disorders. Tissue
specific autoimmunity originates in a specific tissue within an individual organ usually
initiated by a single autoantigen. Dendritic cell MHC presentation of this antigen to cognate
autoreactive T cells amplifies an adaptive immune response that kills the antigen producing
cells. The death of these cells releases a variety of cellular antigens that amplify the
inflammatory immune response (antigen spreading), represented here as stars. In contrast,
systemic autoimmunity autoantigens may originate independently within different tissues
or organs in the body e.g. Connective tissues in Rheumatoid Arthritis (RA) and Systemic
Lupus Erythematosus (SLE). Thus, antigen spreading can originate from multiple tissues
in a variety of affected organs at different times (multiple stars), leading to diverse
inflammatory disease progression from patient to patient. Several tissue specific
autoimmune diseases and their organs of origin are listed (left). Autoimmune diseases
originating in several organs (center), and systemic autoimmune diseases originating
independently in many organs throughout the body are indicated (right).
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Systemic Lupus Erythematosus (SLE), is an autoimmune disease that
progressively invades many tissues throughout the body and is frequently characterized
by the formation of anti-nuclear and anti-chromatin antibodies. These autoantibodies are
generated in response to aberrant apoptosis and decreased clearance of apoptotic cells
which increases the abundance of apoptotic cell blebs containing chromatin. In addition,
the chromatin can be modified during apoptosis further increasing its immunogenicity
(Cohen et al., 2002). Interestingly, mDCs can take up, process and present chromatin
found in these apoptotic blebs to T cells. Dendritic cell presentation of this modified
chromatin stimulates activation of autoreactive T helper cells, leading subsequently to the
formation of autoantibodies by autoreactive B cells. The deposition of immune
complexes formed by anti-chromatin autoantibodies and modified chromatin on cell basal
membranes stimulates a local inflammatory response (Bouts et al., 2012). Further,
autoreactive T cells that bind nuclear antigens such as DNA and histones or small
ribonucleoproteins including Smith (Sm) antigens and U1 and heterogeneous
ribonucleoprotein (hnRNP) A2, to their T cell receptors, were shown to be associated
with SLE development (Seitz & Matsushima, 2010). Taken together, this data suggests
that chromatin, Smith antigens and ribonucleoproteins are potential autoantigen
candidates for development of SLE.
Rheumatoid arthritis (RA), is another well-known systemic autoimmune disease
that affects connective tissues throughout the body. RA-related autoantibodies
demonstrate reactivity to citrullinated proteins and peptides designated as anticitrullinated protein antibodies (ACPA) (Holers, 2013). The process of citrullination
removes positive charges from the antigen via replacement of arginine with citrulline.
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The alteration in charge can modify secondary and tertiary protein structure, thereby
increasing the binding affinity to MHC receptors (Beltrami et al., 2008). The citrullinated
proteins, now altered in structure from normal body proteins, may be recognized by the
immune system as foreign and thus, potential autoantigens intregal to the development of
RA. In agreement with this concept, autoreactivity towards a variety of self-proteins has
been associated with the onset and progression of RA. Several of the antigens described
are joint-derived proteins, such as type II collagen and human cartilage-derived
glycoprotein HCgp39 (Tsark et al., 2002). These experimental findings suggest the
possibility of treating both tissue specific and systemic autoimmune diseases by targeting
several specific autoantigens characteristic of disease development.
Type 1 diabetes is a juvenile onset form of diabetes resulting from autoimmune
destruction of insulin-producing β cells in the pancreatic islets of Langerhans. Type 1
diabetes can be treated in a palliative fashion with exogenous insulin injection. However,
the increasing prevalence of this disease, its progressive complications and the lack of
effective curative and preventive strategies demands a significant research effort to
identify promising therapies capable of restoration of immunological tolerance. At
present, no effective, safe and economical treatment exists to control the onset and
progression this life-long debilitating disease (Marin-Gallen et al., 2010). For this reason,
the non-obese diabetic (NOD) mouse, a widely used animal model presenting the
dominant symptoms of human T1D autoimmunity, is frequently used for studying the
mechanisms underlying T1D onset and progression (Leiter, Prochazka, & Coleman,
1987).
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Based on the presence of specific autoantigens known to elicit diabetes onset, T1D has
been identified as a model prototypic tissue-specific autoimmune disease. Hyperglycemia
develops in T1D when insulin presenting DCs encounter naive insulin reactive T cells in
the periphery. During this interaction, the DCs guide autoreactive T cell differentiation
into inflammatory effector cells that arrest insulin production by inducing β-cell
apoptosis. Little is known concerning the kinetics and phenotype of DCs in the NOD
mouse pancreas during T1D development. While peri-islet accumulation of cDCs can be
observed in NOD mice as early as 4 weeks of age, pDCs were shown to accumulate
around the islets of Langerhans beginning later at 10 weeks of age. Peri-islet dendritic
cell accumulation was found to be concomitant with the influx of lymphocytes (WelzenCoppens, van Helden-Meeuwsen, Leenen, Drexhage, & Versnel, 2013). Ablation of total
DCs in NOD mice led to loss of CD4+ T cell activation, insulitis, antibody production and
pancreatic infiltration with pro-inflammatory Th1/Th17 cells (Saxena, Ondr, Magnusen,
Munn, & Katz, 2007a). The authors further demonstrated that reintroduction of mDCs to
the DC ablated mice induced insulitis and diabetes. Together, these results demonstrate
that DCs are key players in the onset of tissue specific autoimmunity.
The state of dendritic cell activation is critical for determination of their function as
tolerogenic or inflammatory DCs. An important feature of tolerogenic DCs is their ability
to secrete the immuno-regulatory cytokine, TGF-β as well as the anti-inflammatory
cytokine IL-10 which can suppress T cell responses by inhibiting T cell secretion of IL-2
and IFN-γ (Vieira et al., 1991). Studies in the NOD mouse have shown that mDCs can
exhibit a hyper-inflammatory phenotype (Tisch & Wang, 2009; Weaver et al., 2001).
Specifically, NOD mouse mDCs have been shown to generate an elevated capacity for
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stimulation of T cells and secretion of proinflammatory cytokines such as IL-12. Further,
in vitro studies have shown that maturation of moDCs is inhibited in the presence of
exogenous IL-10. The resultant DCs become capable of inducing T cell anergy and Treg
cell differentiation (Steinbrink, Wolfl, Jonuleit, Knop, & Enk, 1997).
Multiple sclerosis is a chronic inflammatory disease of the central nervous system
(CNS) associated with an autoimmune response against components of myelin, including
myelin basic protein (Martino & Hartung, 1999). Experimental autoimmune
encephalomyelitis (EAE), the animal equivalent of MS, is the prominent tool by which
researchers studying MS have investigated the disease process. Various versions of the
model are under investigation to study the mechanisms of immunopathogenesis and new
treatments for MS. New treatment strategies are frequently tested in a chronic EAE
mouse model and when successful, the treatment can be considered for human therapy.
Over the last two decades, the knowledge of immunopathogenesis in MS has grown to
define MS as a multifocal demyelinating disease mediated by an autoimmune response to
several self-antigens. Although neurological deficits in MS may be the result of a
combined cellular and humoral autoimmune attack on the myelin sheath, MS has long
been considered a predominantly T cell-mediated autoimmune disease (Viglietta,
Baecher-Allan, Weiner, & Hafler, 2004). However, it is clear that T cells are not the only
immune cell type involved in MS and EAE disease pathogenesis. The characterization of
DCs during the course of EAE development indicates that different DC subsets serve
distinct functions. For example, conventional DCs are involved in disease development,
while plasmacytoid DCs that produce interferons (IFN) are important in the development
of Treg cells and disease resolution (Bailey-Bucktrout et al., 2008). In MS, recent
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experimental findings highlight the upregulation of TLR7 mediated by interferon-β (IFNβ) in pDCs. Upregulation of TLR7 in pDCs and consequently increased activation of
pDCs by TLR7 ligands could be considered a novel immunoregulatory mechanism for
IFN-β (Derkow et al., 2013). A critical role for IFN-β was demonstrated in a recent
finding in which the pro-inflamatory cytokine induces expression of the IL7Rα receptor
(McKay et al., 2013). Expression of IL7Rα, is unequivocally associated with
susceptibility to MS and was shown to be increased in mDCs in a haplotype dependent
manner in response to increases in to IFNβ.
Active participation of DCs in the pathology of MS is supported by their presence
and activation in the CNS of MS patients (Amodio & Gregori, 2012). Myeloid and
plasmacytoid dendritic cells are present in cerebrospinal fluid in non-inflammatory
neurological diseases and elevated in multiple sclerosis and in acute monosymptomatic
optic neuritis (Pashenkov et al., 2002). Particular emphasis has been given to the study of
pDCs involvement based on their importance in stimulating or inhibiting effector T cells
in MS (Bailey-Bucktrout et al., 2008).
In addition to the presence of DCs in cerebrospinal fluid (CSF) and CNS lesions
in MS patients, both phenotypic and functional impairment have also been observed to be
dependent on DC subsets and MS subtypes. Circulating cDCs expressing upregulated
levels of costimulatory molecules and pro-inflammatory cytokines stimulate proinflammatory cytokine secretion by effector T cells. Their infiltration into the inflamed
brain can be attributed to upregulation of C-C chemokine receptor 5 (CCR5) (Nuyts, Lee,
Bashir-Dar, Berneman, & Cools, 2013). Ambivalent functions of pDCs have been
observed in EAE. It was suggested that pDCs promote priming of autoimmune Th17
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lymphocytes in EAE, whereas depletion of pDCs prior to induction of the disease
decreases its severity (Isaksson et al., 2009). Abundant expression of TLR9 in pDCs
appears to be important in the pathogenesis of EAE. Activation of APCs through TLR9
can overcome tolerance and precipitate EAE while TLR9 knockout mice show a
decreased susceptibility to EAE (Ichikawa, Williams, & Segal, 2002; Segal, Chang, &
Shevach, 2000).

Suppression of Tissue Specific Autoimmunity Through DC-interfering Therapeutic
Strategies
A variety of molecular and cellular strategies for suppression of tissue specific
autoimmunity are currently under development (Figure 2). These strategies include
agonist or antagonist mediated interactions, pharmaceuticals, cytokine targeted antibody
therapies and immunosuppressive vaccines. Mechanisms by which DCs may be able to
mediate the suppression of tissue specific autoimmunity are discussed below.
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Figure 2. Potential mechanisms responsible for dendritic cell mediated suppression
of autoimmunity. (Left) Therapeutic strategies for DC mediated therapy for tissue specific
autoimmunity. (Center) Molecular interactions by which these therapeutic strategies may
function to suppress autoimmunity. (Right) Immune cell outcomes following the therapy
that may stimulate immunological tolerance.
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How dendritic cells become activated and the nature of the activation state
remains a question for further investigation. However, it has been shown that Toll-like
receptor 2, (TLR2) can recognize molecular motifs in atypical LPS, peptidoglycan,
lipoteichoic acid, lipoproteins and lipopeptides (Filippi et al., 2011). More recently, it
was shown that chronic administration of the TLR2 agonist Pam3CSK4 could prevent
diabetes onset in NOD mice by inducing DC mediated tolerance (Kim, Lee, Lee, Kim, &
Lee, 2012). Further corroborating these experimental findings, additional research has
shown that TLR2 signaling can modulate immune regulation and alter the progression of
autoimmunity in the NOD mouse. These experimental results suggest a role for TLR2 in
enhancement of CD4+CD25+ Treg proliferation both in a naïve T cell context and during
viral infection, to provide increased protection against development of autoimmune
diabetes (Filippi et al., 2011). Treatment of prediabetic mice with a synthetic TLR2
agonist diminished the onset of T1D and increased the number and function of
CD4+CD25+ Tregs, thereby conferring tolerogenic properties to DCs. The ligation of
dendritic cell TLR2 was also shown to increase their capacity for autoimmune disease
prevention and to promote the proliferation of Tregs (Filippi et al., 2011).
Cyclosporine and tacrolimus, complex non-antibiotic macrolide compounds
isolated from soil fungi and bacteria, are widely used as immunosuppressive agents
following solid organ transplantation. These immunosuppressant drugs were shown to
dampen the inflammatory activity of the immune system by interfering with the activity
and growth of T cells (Cantrell & Smith, 1984). Cyclosporine and tacrolimus cause
immune suppression by binding cytoplasmic cyclophilin and FK-binding proteins
respectively. Generation of these protein complexes induces binding to calcineurin,
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therefore blocking calcineurin’s activation of the T cell transcription factor NFATc. This
blockade results in inhibition of secretion of the inflammatory cytokine IL-2.
Consequently, T-cell proliferation is suppressed as evidenced by the ability of
cyclosporine treated myeloid DCs to suppress the proliferation of allogenic peripheral
blood mononuclear cells (PBMC) (Ciesek et al., 2005). Similarly, stimulation of memory
CD8+ T cells by DCs was impaired by cyclosporine pretreatment. From this study, it was
concluded that cyclosporine differentially alters the function and phenotype of mDCs
leading to a partially impaired capacity to stimulate the activation of allogenic and
autologous T cells. In another study, it was found that cyclosporine A (CsA) impaired the
migration of mouse bone marrow-derived DCs toward macrophage inflammatory
protein-3beta (MIP-3beta) and induced them to retain responsiveness to MIP-1α after
lipopolysaccharide (LPS) stimulated DC maturation in vitro. Administration of CsA in
vivo was shown to inhibit the migration of DCs out of skin and into the secondary
lymphoid organs (Bougneres et al., 1990). Further, it was also shown that cyclosporine
suppresses β cell autoimmunity and rescues islet β cell function (Bougneres et al., 1990).
However, this study indicates that the therapeutic effect of CsA is sustained only with
continuous cyclosporine administration, which unfortunately is associated with
significant adverse effects. Cyclosporine was shown to downregulate DC synthesized
inflammatory cytokines IL-2 and IL-12, suggesting this class of inhibitory molecules may
have an important role in the regulation of DC mediated inflammatory immune responses
(Sauma et al., 2003).
Sirolimus is a complex organic molecule isolated from bacteria, that exerts an
suppressive effect on the immune system but acts differently from the calcineurin
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inhibitors cyclosporine and tacrolimus (Sieber & Baumgrass, 2009). Sirolimus was
shown to inhibit responses to the inflammatory cytokine IL-2, thereby blocking T and B
cell activation. In contrast to cyclosporine and tacrolimus, sirolimus inhibits IL-2
secretion by binding to the cytosolic protein FK-binding protein 12 (FKBP12)
(Quesniaux et al., 1994). The sirolimus-FKBP12 complex blocks the mammalian mTOR
pathway through direct binding to the mTOR Complex1 (mTORC1) (Huang, Bjornsti, &
Houghton, 2003). Resistance to maturation and tolerogenic properties of DCs were
shown to be supported and preserved by conditioning with sirolimus (Fischer, Turnquist,
Taner, & Thomson, 2009). The ability of sirolimus to suppress DC activation suggests
that sirolimus/rapamycin based therapeutic strategies may be effective for the inhibition
of tissue specific autoimmunity.
Parenteral vaccination is generally considered to be the most effective form of
protection against infectious diseases. More recently however, vaccination at mucosal
surfaces and combinatorial vaccination strategies that link immunostimulatory molecules
(adjuvants), to antigens have been developed to further enhance vaccine efficacy.
Prominent among immunological enhancement strategies are the group of bacterial and
plant AB toxins, which include shigatoxin, anthrax toxin, ricin toxin, the heat sensitive
enterotoxin from E. coli and the cholera toxin CTA and CTB subunits (Odumosu,
Nicholas, Yano, & Langridge, 2010). In contrast to the toxic CTA subunit, the non-toxic
CTB subunit displays both carrier and mild immunostimulatory properties (Langridge,
Denes, & Fodor, 2010). When linked to pathogen antigens, CTB can impart immunostimulatory properties that convey increased levels of immune system stimulation in
response to the linked antigen. These vaccination strategies have been broadened further
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to include CTB linkage to “self'” proteins, which paradoxically often result in enhanced
immunological suppression of autoimmunity. Linkage of CTB to an autoantigen was
shown to provide up to a 10,000 fold reduction in the amount of auto-antigen required for
generating immune-tolerance (Arakawa, Chong, & Langridge, 1998; George-Chandy et
al., 2001; Odumosu et al., 2010). In T1D for example, self-proteins become more
strongly immunosuppressive when linked to CTB. In addition to its known capacity to
induce a pro-inflammatory response, oral administration of CTB subunit coupled with
insulin or GAD35 autoantigen, was shown to induce immunological tolerance in NOD
mice (D'Ambrosio, Colucci, Pugliese, Quintieri, & Boirivant, 2008; George-Chandy et
al., 2001; Odumosu et al., 2010).
Morphological changes in DCs incubated with CTB coupled to an autoantigen
included cell enlargement, elongation of dendrites and increased migration of DCs to
draining lymph nodes, as well as increased expression of dendritic cell B7-2/CD86 costimulatory molecules (Isomura et al., 2005; Odumosu et al., 2010). In a recent finding in
our laboratory, incubation of human immature moDCs with CTB-INS autoantigen fusion
protein showed an increase in surface expression of TLR2 with no significant
upregulation in TLR4 expression (Odumosu, Payne, et al., 2011). In contrast, inoculation
of immature dendritic cells (iDCs) with CTB stimulated the biosynthesis of both CD86
and CD83 co-stimulatory factors demonstrating an immunostimulatory role for CTB in
both DC activation and maturation. In comparison, incubation of iDCs with pro-insulin
partially suppressed DC activation, while incubation of iDCs with CTB-INS fusion
protein completely suppressed iDC biosynthesis of both CD86 and CD83 costimulatory
factors. Inoculation of iDCs with CTB-INS fusion protein was shown to dramatically
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increase secretion of the immunosuppressive cytokine IL-10 while suppressing synthesis
of the pro-inflammatory cytokine IL12/23p40 subunit. This result suggests that linkage of
CTB to pro-insulin (INS) could play an important role in mediating DC guidance of Th0
cell development into Treg cells. Taken together, the experimental data suggests that
TLR2 may play a dominant role in CTB-INS mediated prevention of human T1D onset.
Further, fusion of CTB to proinsulin was found to be essential for enhancement of
immune suppression as co-delivery of CTB and insulin did not significantly inhibit
dendritic cell CD86 biosynthesis. Thus, the experimental data supports the hypothesis
that CTB-autoantigen mediated suppression of islet β cell inflammation and
hyperglycemia development is dependent on CTB stimulation of dendritic cell TLR2
receptor activation and co-processing of both CTB and the autoantigen in the same DC
(Odumosu, Payne, et al., 2011).
The first enzyme in the tryptophan degradation pathway, indoleamine 2, 3dioxygenase (IDO) may be an important contributor to DC mediated suppression of
autoimmunity. IDO is the rate-limiting catabolic enzyme encoded by the IDO1 gene
responsible for the degradation of L-tryptophan (L-Trp) to N-formyl kynurenine and its
further degradation products (Najfeld, Menninger, Muhleman, Comings, & Gupta, 1993).
IDO was shown to inhibit DC maturation through tryptophan starvation via a generalized
reduction in cellular energetics and through the generation of secreted kynurenines shown
to be effective in stimulating T cell apoptosis and Treg proliferation [125-128]. Further, it
was recently found that the tryptophan metabolite 3-hydroxyanthranilic acid (3-HAA)
directly inhibits DC activation and is responsible for suppression of inflammatory Th1
cell functions (Lee et al., 2013). Treatment with 3-HAA was shown to significantly
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reduce production of the pro-inflammatory cytokines IL-12, IL-6, and TNF-α in bone
marrow-derived dendritic cells stimulated with LPS. The role of IDO in dendritic cell
function may differ among DC subsets because the ability of DCs to produce IDO does
not seem to be equally distributed among the various DC subsets. The CD8α positive
DCs in mice were shown to express higher amounts of IDO in comparison with CD8αnegative DCs. In response to IFNγ, CD8α-positive DCs were shown to rapidly express
IDO and establish immunological tolerance (Fallarino, Vacca, et al., 2002; Grohmann,
Bianchi, et al., 2003; Harden & Egilmez, 2012).

The Role of Indoleamine 2, 3-dioxygenase in Immune Suppression and
Autoimmunity
Indoleamine 2, 3-dioxygenase (IDO) is a mammalian cytosolic enzyme composed
of two alpha-helical domains with a heme group located between them responsible for
catalyzing the initial step in tryptophan catabolism via the kynurenine degradation
pathway(Sugimoto et al., 2006) (Figure 3). The first and rate-limiting step in this pathway
is the conversion of tryptophan to N-formyl kynurenine, and until recently, this reaction
was thought to be performed by either tryptophan 2, 3-dioxygenase (TDO) or
indoleamine 2, 3-dioxygenase (IDO1)(Heitger, 2011; Yuasa et al., 2009). While TDO is
widely distributed in both eukaryotes and bacteria (Zhang et al., 2007), IDO1 is restricted
to mammals and yeast (Panozzo et al., 2002). A third tryptophan catabolic enzyme,
named indoleamine 2, 3-dioxygenase-2, an indoleamine 2, 3-dioxygenase-like protein or
“proto-indoleamine 2, 3-dioxygenase” (IDO2, INDOL1 or proto-IDO), was recently
described and was found in mammals and in lower vertebrates (Ball et al., 2010). Both
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IDO1 and IDO2 genes are conserved in mammals and are present in tandem on
chromosome 8 (Prendergast, Metz, Muller, Merlo, & Mandik-Nayak, 2014). Both IDO1
and IDO2 share significant identity at the amino acid level (43% for human and mouse
proteins), but are structurally unrelated to the TDO enzyme protein. Expression of IDO2
is found in human DCs, but is not as ubiquitous as IDO1, although IDO2 mRNA can be
detected in the liver, small intestine, spleen, placenta, thymus, lung, brain, kidney and
colon (Metz et al., 2007). The physiological role of IDO2 remains unclear, and unlike
IDO1, its expression is not induced by virus infection or the presence of IFNγ (Ball et al.,
2010). Further, IDO2 is sensitive to inhibition by the D-isomer of 1-methyl tryptophan
(D-1MT), a specific inhibitor of IDO (Metz et al., 2007). The relevant sensitivity of IDO
to inhibition lies predominantly in the putative effect of the D-isomer on suppression of
cancer immune evasion. Interestingly, two non-synonymous single-nucleotide
polymorphisms lie in the coding region of the IDO2 gene, both of which result in a loss
of enzymatic activity (Metz et al., 2007). This observation provides a basis for reducing
the effect of IDO2 in cancer progression (Heitger, 2011).
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Figure 3: Pathways of tryptophan metabolism. Of the dietary tryptophan, 99% is
metabolized via indoleamine 2, 3-dioxygenase (IDO) and tryptophan 2, 3-dioxygenase
(TDO) to form kynurenine degradation products (red arrows). Additional enzymes in the
pathway, kynurenine aminotransferase (KAT), monoamine oxidase (MAO), quinolinicacid phosphoribosyl transferase (QPRT) and 3-hydroxyanthranilic acid oxidase (HAO),
promote immune suppression through the inhibition of pro-inflammatory T-cells and
induction of regulatory T-cell populations that stimulate pathologies as a result of
insufficient or excessive immune suppression.
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Mechanisms of IDO1 Induction and Function
Sustained access to nutrients is a fundamental metabolic requirement for
prokaryotic and eukaryotic cell maintenance and proliferation. Controlling the supply of
available nutrients is an ancient strategy for regulation of cellular responses to stimuli.
Aside from its role as one of the limiting essential amino acids in protein metabolism,
tryptophan (TRP) serves as precursor for synthesis of the neurotransmitters serotonin and
tryptamine as well as for synthesis of the anti-pellagra vitamin nicotinic acid and the
hormone melatonin (Heine, Radke, & Wutzke, 1995). By involvement in a variety of
metabolic pathways, TRP and its metabolites regulate neurobehavioral effects that
include appetite, the sleeping-waking-rhythm and pain perception. TRP is the only amino
acid that binds high levels of serum albumin (Heine et al., 1995; Sasaki, Ohta, Shinohara,
& Ishiguro, 1999). Through IDO degradation of tryptophan, cells that express the enzyme
mediates potent effects on metabolic events responsible for innate and adaptive immune
responses to inflammatory insults. In addition, IDO1 was shown to alter immune
responses through a variety of mechanisms dependent the regulation of cell metabolism.
In the sections that follow, we will identify mechanisms by which IDO1 activation was
shown to modulate eukaryotic cell functions leading to stimulation or suppression of the
diseased state.
Indoleamine, 2, 3-dioxygenase is not constitutively expressed in cell systems.
Rather, various stimuli and signaling pathways induce transcription and translation of
metabolically active IDO1 enzyme protein. Various transcription factors were shown to
regulate the expression of IDO1 (J. C. Mbongue et al., 2015; Tas et al., 2007). The IDO1
promoter contains nucleotide sequences that allow regulation through interferon sequence
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response-like elements (ISRE), GAS (palindromic gamma-activated sequences) and noncanonical NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells)
consensus sequences ("Adsorption Technologies and Blood Purification Procedures.
Proceedings of an international conference in honor of Horst Klinkmann on his 65th
birthday. May 5-7, 2000," 2002; Chon, Hassanain, Pine, & Gupta, 1995; Du, SoteroEsteva, & Taylor, 2000). Mutation or deletion of portions of two ISRE cis-acting
(ISRE1 and ISRE2) response elements resulted in decreased IDO1 expression levels
(Robinson, Hale, & Carlin, 2005b). Deletion of ISRE1 decreased the ability of IFN-γ to
induce IDO1 by 50-fold and point mutations at two alanine residues of ISRE2 at -111
decreased the ability of IFN-γ to induce IDO1 by 4-fold (Konan & Taylor, 1996)., The
distance between these response elements does not influence IDO1 expression as the
deletion of 748 bps between the elements had no effect on IDO1 synthesis (Konan &
Taylor, 1996). In addition to the ISRE elements, a nucleotide sequence with a partial
homology to the IFN-gamma-responsive sequence (GAS) was shown to be located in the
promoter region of the IDO1 gene (Robinson et al., 2005b). In 3B6Acells, a cell line with
a defect in IDO1 activity, Stat 1α was shown to bind to GAS and restore IDO1 induction
(Du et al., 2000). The consensus sequence PuGGAGAPyTTPu is required for noncanonical binding of NF-κB (Bonizzi et al., 2004). The IDO1 promoter contains three
partial RelB/p52 binding sites: AGGAGACACA, GGGAGACAGA, and
AGGAGAAAGA around position -2000 (Bonizzi et al., 2004; Puccetti & Grohmann,
2007). Manches et. al. demonstrated by luciferase assay and ChIP analysis experiments
that RelB bound directly to non-canonical NF-κB binding sites in the promoter regions of
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mammalian DNA and drives IDO1 gene expression (Manches, Fernandez, Plumas,
Chaperot, & Bhardwaj, 2012; Robinson, Hale, & Carlin, 2006).
There are several receptor/ligand signaling pathways upstream of these transcription
factors that can regulate IDO expression. Toll-like receptors (TLRs), tumor necrosis
factor superfamily members (TNFRs), interferon beta receptor (IFNBR), the interferon
gamma receptor (IFNGR), transforming growth factor beta receptors (TGFBRs), and the
aryl hydrocarbon receptor (AhR) all can activate signaling mechanisms that either induce
or maintain IDO1 expression. Stimulation of TLR3 and TLR4 was shown to induce IDO1
production in dendritic cells, while TLR7/8 was shown to upregulate IDO1 in
monocytes(Filippi et al., 2011; Swiecki et al., 2011)The mechanism by which TLR4
ligation activates IDO1 expression was shown to contribute to autocrine signaling from
TNF-α and/or IFN-β (Li, Katz, & Spinola, 2011) (Figure 4). For example, LPS induction
of IDO1 in a monocyte cell line is decreased when TNF-α is blocked with neutralizing
antibodies (Fujigaki et al., 2001). Ligation of TLR4 activates both MyD88-dependent and
MyD88-independent adaptor driven signaling pathways which leads to the activation of
canonical NF-κB and IRF3 transcription factors. Activation of NF-κB leads to expression
of the pro-inflammatory cytokine TNF-α, while the transcription factor IRF3 operating in
conjunction with NF-κB induces the pro-inflammatory cytokine IFN-β. These cytokines
bind their receptors (TNFR and IFNAR) to activate the non-canonical NF-κB and JAKSTAT signalling pathways which leads to the transcription and translation of IDO protein
(Horvath, 2004).
The ligation of IFNGR by IFN-γ is another established pathway known to
stimulate production of IDO in immune cells. In human monocyte derived DCs,
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stimulation with IFN-γ induces IDO through the JAK/STAT signalling pathway
(Horvath, 2004; Jurgens, Hainz, Fuchs, Felzmann, & Heitger, 2009; Li et al., 2011). Of
greater interest is the regulation of IDO by TGF-β. Unlike the previous signalling
mechanisms, TGF-β was shown to produce delayed expression of IDO in plasmacytoid
dendritic cells (pDCs) that is long lasting and stable (Pallotta et al., 2011). Upon binding
to the TGF-beta receptor (TGFBR), both the Smad-dependent and Smad-independent
pathways (phosphatidylinositol-3-OH kinase (PI(3)K) are activated and signal the
induction of non-canonical NF-κB pathway upregulation of IDO biosynthesis (Shi &
Massague, 2003). Upon stimulation of IDO1 biosynthesis, TGF-β generates a positive
feedback loop for sustained production of TGF-β and IDO1 through a PI (3) K dependent
mechanism (Pallotta et al., 2011). This signalling mechanism relies on the ability of TGFβ to activate the signalling capability of IDO1 which is described in detail in the
following sections. IDO1 signalling mediated by TGF-β promotes transcription and
translation of more TGF-β which in turn continues to upregulate IDO1 production
(Figure 5).
In addition to TGF-β, the aryl hydrocarbon receptor (AhR) was also shown to
play a role in IDO production. In mouse bone marrow derived DCs, Nguyen et.al.
demonstrated that AhR -/- DCs do not produce IDO following LPS or CpG treatment
(Nguyen et al., 2010). This result suggests AhR may be necessary for TLR4 and TLR9
induction of IDO in DCs. Secondly, kynurenines produced in response to IDO’s
enzymatic activity can bind and activate AhR as an endogenous ligand. (Figure 5). Vogel
et al. demonstrated that AhR can partner with RelB, to associate with DNA by binding
the IDO1 promoter at putative dendritic cell responses element (DRE) consensus
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sequences and thus promote AhR-dependent induction of IDO1 (Mezrich et al., 2010a;
Vogel et al., 2013).
Based on the observation that CD40 ligand (CD40L) induces IDO1 biosynthesis
through non-canonical NF-κB signaling in human DCs (Tas et al., 2007), NF-κB
signaling pathway involvement in cholera toxin B subunit – proinsulin fusion protein
(CTB-INS) induced IDO1 biosynthesis was assessed in a study conducted in our
laboratory. In this study, NF-κB activation for vaccine up-regulation of IDO1 was
identified with the help of two specific NF-κB pharmacological inhibitors, ACHP and
DHMEQ (J. C. Mbongue et al., 2015).
Although there are various mechanisms known promote IDO induction, the
function of IDO remains consistent, to promote immune suppression. In response to
inflammatory stimuli, IDO functions as an immune regulator to keep pro-inflammatory
signalling in check. Conversely, IDO is essential for the maintenance of immune
tolerance. Mechanisms by which IDO exerts its immunosuppressive effects are discussed
in the following sections.
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Figure 4: Mechanism of IDO1 induction in human dendritic cells. Transcription and
Translation: Several molecular stimuli and signaling pathways were shown to induce the
transcription and translation of metabolically active IDO1 enzyme (Fallarino et al., 2009;
Konan & Taylor, 1996; Robinson, Hale, & Carlin, 2005a; Tas et al., 2007). The IDO1
promoter contains nucleotide sequences that allow regulation of transcription through
ISRE upstream consensus sequences, GAS (palindromic gamma-activated sequences) and
non-canonical nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB),
(Lind et al., 2008; Puccetti & Grohmann, 2007; Robinson et al., 2005a). In addition, the
IDO1 promoter region contains three partial non-canonical RelB/p52 binding sites:
AGGAGACACA, GGGAGACAGA, and AGGAGAAAGA located near position -2000,
which is located downstream of NF-κB-driven IDO upregulation following stimulation of
TLR4, INFGR, IFNAR, TNFR and CD40R signaling pathways (Manches et al., 2012).
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Figure 5: The TGF-β–IDO–SHP axis. The TGF-β–IDO–SHP axis activates the noncanonical NF-κB pathway (Pallotta et al., 2011). In splenocytes, SHP-1 inhibits the protein
kinase IRAK1(An et al., 2008) and tips the balance of activation of canonical versus noncanonical NF-κB signaling pathway in favor of the latter, resulting in up-regulated
production of type I interferon (Pallotta et al., 2011). In addition to TGF-β, the aryl
hydrocarbon receptor (AhR) has also been shown to play a role in IDO production
(Mezrich et al., 2010a; Nguyen et al., 2010). Interestingly, kynurenines produced from
IDO’s enzymatic activity can also bind and activate as an endogenous ligand, AhR
(Mezrich et al., 2010a). Abbreviations: IFN (α β, γ,): interferon alpha, beta, gamma; TGFβ: transforming growth factor-beta; TNF: tumor necrosis factor; TLR4: toll-like receptor
4; TRAF: TNF-receptor associated factors; TRIF: TIR-domain-containing adapterinducing interferon-β; SHP: orphan nuclear receptor small heterodimer partner; SMAD:
extracellular signal transducers from TGF-β ligands to the nucleus; IRF (1, 3): and
interferon regulatory factor 1,3.
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Indoleamine 2, 3 dioxygenase was shown to inhibit DC maturation through
tryptophan starvation via a generalized reduction in cellular energetics and through the
generation of secreted kynurenines known to be effective in stimulating Th cell apoptosis
(J. C. Mbongue et al., 2015). Additional experimental findings showed that in addition to
tryptophan starvation, paracrine effects of secreted kynurenine tryptophan degradation
products may contribute to DC tolerogenesis through increased recruitment of regulatory
T-cells (Fallarino et al., 2006; Pop et al., 2007; Zaher, Germain, Fu, Larkin, & George,
2011). The immunosuppressive activity of IDO was first speculated to be solely a
function of the physical depletion of tryptophan from the intracellular environment, thus
starving the metabolism of DCs, T cells, and other effector cells of the immune system.
Tryptophan starvation is sensed in eukaryotic cells through activation of the general
control non-repressed 2 (GCN2) kinase, which directly binds uncharged tRNAs (Harden
& Egilmez, 2012; J. Mbongue, Nicholas, Firek, & Langridge, 2014; Munn et al., 2005).
Tryptophan depletion was shown to induce the GCN2 pathway, down-regulate the CD3
ζ-chain in CD8+ T cells, and to inhibit Th17 cell differentiation (Fallarino et al., 2006;
Munn et al., 2005). Recent work provided definitive evidence of an important role for
kynurenine metabolites in IDO-mediated modulation of immune function (Belladonna,
Orabona, Grohmann, & Puccetti, 2009; Belladonna et al., 2007; Zaher et al., 2011).
Further, these studies also demonstrated IDO-dependent apoptosis of thymocytes and
terminally differentiated antigen-specific CD4+ T cells (Fallarino, Grohmann, et al.,
2002; Grohmann, Fallarino, & Puccetti, 2003). Previous work showed that transgenic
DCs with high levels of IDO expression and tryptophan metabolites (i.e. l-kynurenine, 3hydroxykynurenine and 3-hydroxyanthranilic acid), were able to irreversibly suppress
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allogeneic T-cell proliferation in vitro (Fallarino et al., 2006; Grohmann, Fallarino, et al.,
2003; Terness et al., 2002). In these studies, immuno-suppressive tryptophan catabolites
were shown to exert a cytotoxic action on CD3+ cells. This action preferentially affected
activated T cells and gradually increased with exposure time. In addition to T cells, B
cells and natural killer (NK) cells were also killed while DCs remained unaffected
(Terness et al., 2002). Similar results were obtained in another study where three
tryptophan catabolites (i.e. l-kynurenine, picolinic acid and quinolinic acid) were shown
to be responsible for IDO induced inhibition of T- and NK-cell proliferation potentiated
by tryptophan depletion (Frumento et al., 2002; Grohmann, Fallarino, et al., 2003).
The immunosuppressive effect of IDO was recently shown in NOD mice to
require both enzymatic and signaling functions (Pallotta et al., 2014; Pallotta et al.,
2011). Treatment of mouse plasmacytoid DCs with transforming growth factor-β (TGFβ) conferred regulatory effects on IDO1 that were shown to be mechanistically separable
from its enzymatic activity (Belladonna et al., 2007; Belladonna et al., 2008; Pallotta et
al., 2011). The TGF-β–IDO axis was found to mediate durable regulatory functions
resulting in the generation and maintenance of regulatory T cell populations (Belladonna
et al., 2009; Pallotta et al., 2011). In these studies conducted by Pallotta et al., IDO
signaling activity was triggered in plasmacytoid dendritic cells (pDCs) by transforming
growth factor-β (TGF-β) through the non-canonical NF-κB pathway resulting in the
induction of long-lasting IDO expression and autocrine TGF-β production in a positive
feedback loop (Pallotta et al., 2011). In addition, IDO was found to be involved in
intracellular signaling events responsible for self-amplification and maintenance of a
stable regulatory pDC phenotype (Figure 6).
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The aryl hydrocarbon receptor (AhR) was shown to cause immune suppression
after binding dioxin (Opitz et al., 2011). The aryl hydrocarbon receptor may be central to
naïve T cell differentiation into Foxp3+ regulatory T cells (Tregs) rather than proinflammatory Th17 lymphocytes (Mezrich et al., 2010b). In this study performed by
Mezrich and his colleagues, kynurenines were shown to activate AhR leading to AhRdependent Treg generation. Together, the above studies reinforce the involvement of IDO
in the generation of Tregs, as well as highlighting the central importance of IDO’s
signaling capabilities.

The Role of IDO in Immune Suppression
Acute and chronic graft rejection during solid organ and tissue transplantation is a
demanding challenge for surgeons and patients. Current treatments employ a general
immunosuppressive regimen which leaves the patient vulnerable to common pathogens
and immuno-suppressive therapy usually must be administered lifelong with potentially
severe side effects (Fukui et al., 2011; Iwata et al., 2014). In vivo experiments have
shown that IDO1 gene knockout mice experience acute rejection of transplanted MHC
mismatched grafts, while wild-type mice with high tryptophan catabolism experienced
long-term graft survival (Sucher et al., 2012). Further experiments have shown that the
dendritic cell costimulatory factor CD83 (sCD83) induced long-term IDO expression in
DCs via up-regulation of TGF-β both in vitro and in vivo, resulting in the induction of a
long-lasting allograft tolerance in combination with a locally restricted
immunosuppressive environment (Bock et al., 2013).
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While viruses and bacteria do not express IDO, they can create an advantage for
their replication by stimulating the enzyme’s catabolic activity to suppress unwanted
immune responses in mammalian cells. Specifically, human immune deficiency virus
(HIV) and Epstein Barr virus are two well-known virus examples that increase cellular
levels of IDO during infection (Boasso et al., 2007; Grant et al., 2000; W. L. Liu et al.,
2014). It has been suggested that HIV may induce IDO expression to inactivate the
human immune system. HIV is a lentivirus (retrovirus subgroup), that infects CD4+ T
cells, macrophages, and dendritic cells (Cunningham, Donaghy, Harman, Kim, &
Turville, 2010; Douek, Roederer, & Koup, 2009). Facilitating the spread of HIV
infection, the virus evades the direct killing mechanisms of CD8+ cytotoxic lymphocytes
that recognize HIV infected cells by inducing IDO synthesis (Fauci, Pantaleo, Stanley, &
Weissman, 1996). Earlier studies show that HIV stimulates IDO biosynthesis to block the
function of pro-inflammatory CD4+ T-helper cells and to stimulate immunosuppressive
Treg cell responses (Boasso et al., 2007). A recent report showed that IDO1 was
overexpressed in lymphoid tissues during HIV infection (Boasso et al., 2007). Further,
increased tryptophan catabolism, measured as an increase in the kynurenine/Trp ratio,
was shown to occur in HIV-infected patients (Fuchs et al., 1990). Together, these data
suggest that HIV depends on the immunosuppressive properties of IDO to facilitate the
immune evasion processes.
The Epstein–Barr virus (EBV), also referred to as human herpesvirus 4 (HHV-4),
is one of eight virus strains in the herpes virus family and is one of the most common
human pathogenic viruses. The Herpes virus 4 strain is best known as the cause of
infectious mononucleosis (glandular fever)(Linde, 1996). This virus strain was also
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shown to be associated with specific forms of cancer including Hodgkin's lymphoma,
Burkitt's lymphoma, nasopharyngeal carcinoma and HIV associated conditions including
hairy leukoplakia and central nervous system lymphomas (Linde, 1996; Maeda et al.,
2009). The EB virus is known to infect monocytes/macrophages, intraepithelial
macrophages, and Langerhans dendritic cells (Tugizov et al., 2007; Walling, Ray,
Nichols, Flaitz, & Nichols, 2007). Infection of monocytes with EBV was shown to
suppress their phagocytic and antiviral activity (Savard, Belanger, Tardif, et al., 2000;
Savard, Belanger, Tremblay, et al., 2000). More recently, EBV infection was shown to
induce IDO mRNA, protein, and enzymatic activity in human monocyte-derived
macrophages (MDMs) (W. L. Liu et al., 2014). This important finding suggests EBVmediated IDO expression in nasopharyngeal carcinoma tumor stroma may provide an
immune-suppressed T cell microenvironment that facilitates virus infection.
While escape from the immune response is essential for cancer progression,
mechanisms underlying this process remain unclear. The catabolism of tryptophan in
tumor cells mediated by IDO1 has been increasingly identified as a critical microenvironmental factor involved in aiding immune escape through suppression of antitumor immunity (Muller & Prendergast, 2005; Platten, von Knebel Doeberitz, Oezen,
Wick, & Ochs, 2014). Stimulation of the tryptophan catabolic pathway was shown to
create an immuno-suppressive milieu in tumors and in tumor-draining lymph nodes
through accumulation and secretion of immunosuppressive tryptophan catabolites that
lead to induction of T-cell anergy, apoptosis and increased proliferation of
immunosuppressive regulatory T cells (Tregs) (Platten, Wick, & Van den Eynde, 2012).
Thus, IDO is capable of biasing the immune system towards tumor support by elevating
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the level of pathogenic inflammation in the tissue microenvironment surrounding the
tumor. Clinically, studies of ovarian, endometrial, and colorectal cancer have shown
increased expression of IDO1 was associated with poor survival outcomes(Platten et al.,
2012). Based on the enzyme’s immunosuppressive functions, IDO1 is becoming
established as a target for drug discovery in cancer immunotherapy (Lob et al., 2008;
Platten et al., 2014). Human primary gastric, colon and renal cell carcinomas were shown
to constitutively express both, IDO1 and IDO2 mRNA, whereas cancer cells lines
generally required induction of IDO by interferon-gamma (IFNγ) (Lob et al., 2009). In
this study, treatment of HeLa cells with IDO1 siRNA resulted in prevention of tryptophan
degradation.
Glioblastoma multiforme (GBM) is an aggressive adult brain tumor with a poor
prognosis. One hallmark of GBM is the gradual accumulation of immunosuppressive and
tumor-promoting CD4+ FoxP3+ regulatory T cells (Tregs) (Jacobs et al., 2010;
Wainwright et al., 2012). Wainwright and colleagues, investigated the role of IDO1 in
brain tumors and its impact on Treg recruitment and found that IDO1 expression
increased recruitment of immunosuppressive Tregs that lead to tumor outgrowth
(Wainwright et al., 2012). In contrast, IDO1 deficiency was shown to decrease Treg
recruitment and enhance T-cell-mediated tumor rejection. This data suggests a critical
role for IDO1-mediated immunosuppression in glioma and supports the continued
investigation of IDO-Treg interactions in the context of suppression brain tumor
outgrowth.
For some time, the significance of IDO promotion of cancer survival was
questioned by its observed function in prevention of allogenic rejection and by evidence
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that IDO is overexpressed in most tumors and tumor draining lymph nodes (Friberg et al.,
2002; Uyttenhove et al., 2003).
A major question is how does IDO become deregulated in cancer cells? A
possible answer is emerging from studies of Bin1 a tumor suppressor gene that is often
inactivated during cancer seems to inhibit cancer development to a significant extent by
limiting immune escape (Muller, DuHadaway, Donover, Sutanto-Ward, & Prendergast,
2005). Studies aimed at understanding how Bin1 restricts tumor outgrowth identified the
establishment of immune tolerance through deregulation of IDO1 as a likely explanation
(Muller et al., 2005). Deletion of the Bin1 gene from mammalian cells resulted in an
increased IDO1 gene expression stimulated by IFN-γ. In this study in vitro
transformation of Bin1-null and Bin1- expressing primary mouse embryo keratinocytes
with c-myc and mutant Ras oncogenes produced cell lines with similar in vitro growth
properties. However, when these cells were grafted into syngeneic animals, the Bin1-null
cells formed large tumors, whereas the Bin1-expressing cells formed only indolent
nodules. Together, these findings suggest that the overexpression of IDO1, which
accompanies Bin1 loss, promotes tumorigenicity by enabling immune escape. The
attenuation of Bin1 together with IDO overexpression observed in human cancers
warrants further evaluation of the relationship between these two metabolic events.
Together the data suggest tumors exploit induction of IDO1 as a dependable
mechanism for survival through enhanced immunosuppression of immunity. Recent
studies using ex-vivo antigen-loaded DCs loaded with tumor antigens were shown to
improve the immune response to the cancer (A. K. Palucka, Ueno, Fay, & Banchereau,
2008; K. Palucka, Banchereau, & Mellman, 2010). The goal of recent DC derived tumor
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vaccines are to elicit the CD8+ T-cell response(K. Palucka, Ueno, & Banchereau, 2011).
However, in order to reach this goal, the DC elicited adaptive immune response must be
able to overcome the immunomodulatory effects of the tumor (A. K. Palucka et al., 2008;
K. Palucka et al., 2010; K. Palucka et al., 2011).
Organ and tissue-specific autoimmunity requires the initial release of specific
autoantigens characteristic of a given tissue or organ that can be recognized by DC
pattern recognition receptors (PRR)(J. Mbongue et al., 2014). Prototypic tissue-specific
autoimmune diseases that are presented here include type 1 diabetes (T1D) and multiple
sclerosis (MS). Type 1 diabetes is an autoimmune disorder in which auto-reactive T cells
selectively destroy the pancreatic islet insulin-producing beta cells. The genetically
diabetes-prone non-obese diabetic (NOD) mouse strain is a murine model of human type
1 diabetes. Diabetic NOD mice generally die from the effects of hyperglycemia,
reflecting T cell–mediated destruction of the insulin producing pancreatic islet β cells.
The predisposition of NOD mouse development of autoimmunity may involve defects in
mechanisms of both peripheral and central tolerance (Kishimoto & Sprent, 2001; Pallotta
et al., 2014). Defective in IDO1 expression, NOD mouse pDCs fail to up-regulate IDO1
in response to stimuli such as the pro-inflammatory cytokine IFNγ, one of the most
potent inducers of IDO expression and catalytic function (Fallarino et al., 2004; Pallotta
et al., 2014). Studies conducted by Pallotta et al. showed that forced IDO1 expression in
dendritic cells rescues both IDO enzymatic and signaling activities, providing substantial
proof that global IDO defects predispose NOD mice to autoimmunity (Pallotta et al.,
2014).
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In contrast, multiple sclerosis (MS), is a chronic inflammatory disease of the
central nervous system (CNS) associated with an immune reaction against components of
the myelin sheath, predominantly myelin basic protein (Martino & Hartung, 1999).
Experimental autoimmune encephalomyelitis (EAE), the animal equivalent of MS, is a
prominent animal model that researchers studying MS use to assess disease progression.
Based on their immunosuppressive properties, human mesenchymal stem cells (hMSC)
provide a promising tool for cell-based therapies of autoimmune diseases including MS.
Murine MSC (mMSC) were used to characterize and optimize route of administration,
motility, cellular targets, and immunosuppressive mechanisms in mouse models of
autoimmune diseases, such as experimental autoimmune encephalomyelitis (EAE)(Lanz
et al., 2010). Tryptophan catabolism by IDO1 is a major endogenous metabolic pathway
that tightly regulates immune responses throughout the nervous system. The activity of
IDO1 contributes to the immunosuppressive phenotype of hMSC (Lanz et al., 2010). In a
study conducted by Lanz and his colleagues, the authors showed that although IDO1 is
inducible in bone marrow-derived mMSC by pro-inflammatory stimuli such as
interferon-γ (IFN-γ) and ligands of toll-like receptors (TLR), disease induction does not
lead to catabolism of tryptophan in vitro (Lanz et al., 2010). Thus, IDO1 does not appear
to be involved in mMSC-mediated immunosuppression in EAE. While mMSC
suppressed the activation of antigen-specific myelin oligodendrocyte glycoprotein
(MOG)-reactive T-cell receptor (TCR) in transgenic Th cells in MSC-T cell co-cultures,
neither pharmacologic inhibition nor genetic ablation of IDO1 reversed this suppressive
effect (Lanz et al., 2010). However in this study, systemic administration of both, IDO1proficient and phenotypically identical IDO1-deficient mMSC, equally resulted in
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amelioration of EAE. Thus, mMSCs, unlike hMSCs, do not display IDO1-mediated
suppression of antigen-specific T-cell responses. During experimental autoimmune
encephalomyelitis (EAE), IDO1 induction was shown to down-regulate neuroinflammation (Sakurai, Zou, Tschetter, Ward, & Shearer, 2002). Inhibition of IDO
activity by daily subcutaneous administration of the specific IDO inhibitor 1-methyl-DLtryptophan was shown to significantly exacerbate EAE (Kwidzinski et al., 2003). Thus,
local expression of IDO during inflammation may be mechanism for self-protection that
limits antigen-specific immune responses in the CNS.

Immune Suppressive Vaccines: The Case for CTB-Autoantigens and their
Relationship to Indoleamine 2, 3 dioxygenase
Until the present, prevention of infectious disease by exposing the immune system
to a weakened, non-toxic or dead infectious agent has been the traditional method of
vaccination (Gupta, 2011; Harrison, 2005; Odumosu et al., 2010). Prominent among
immunological enhancement or adjuvant strategies are the bacterial and plant AB subunit
toxins, which include shiga toxin, anthrax toxin, ricin toxin, the heat sensitive enterotoxin
from E. coli, and the cholera toxin CTA and CTB subunits (Odumosu et al., 2010). In
contrast to the toxic CTA subunit, the nontoxic CTB subunit displays both carrier and
mild immune-stimulatory properties (Denes et al., 2005). When linked to pathogen
antigens, CTB was shown to impart immune-stimulatory properties that convey increased
levels of immune stimulation in response to the linked antigen (Bergerot et al., 1997).
However, when CTB is linked to “self” proteins, the result is often enhanced
immunological suppression of autoimmunity. Demonstrating the adjuvant capability of
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the cholera toxin B subunit, the linkage of CTB to an autoantigen (ovalbumin), was
shown to provide up to a 10,000-fold reduction in the amount of autoantigen required for
generating immune-tolerance (Arakawa et al., 1998; George-Chandy et al., 2001; J.
Mbongue et al., 2014; Odumosu et al., 2010). In type 1 diabetes, self-proteins like insulin
become more strongly immunosuppressive when linked to CTB. Oral administration of
CTB subunit coupled with insulin or GAD35 autoantigen was shown to induce
immunological tolerance and suppression of type 1 diabetes in NOD mice (D'Ambrosio
et al., 2008; George-Chandy et al., 2001; Odumosu, Nicholas, Payne, & Langridge,
2011).
Additional forms of tissue specific autoimmunity were capable of being
suppressed by CTB-linked autoantigens. Behcet's Disease (BD) is an inflammatory tissue
specific autoimmune disorder characterized by uveitis, oral and genital ulcers as well as
cutaneous, vascular, joint and neurological inflammation (Kaneko et al., 1997; Pickering
& Haskard, 2000). Fusion of an uveitogenic HSP60 derived-peptide (aa 336-351) with
CTB resulted in significant protection against mucosally induced uveitis and other
Behcet's disease symptoms (Phipps et al., 2003; Stanford et al., 2004).
Multiple sclerosis (MS) is an inflammatory disease of the central nervous system
(CNS) characterized by localized myelin destruction and axonal degeneration (Clements
et al., 2003). An autoimmune reaction against myelin antigens of the CNS was shown to
contribute to the immunopathological mechanisms of MS (Anderson & Rodriguez,
2011). Myelin oligodendrocyte glycoprotein (MOG) is a key CNS-specific autoantigen
for primary demyelination in multiple sclerosis. Fusion of CTB with myelin
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oligodendrocyte glycoprotein (MOG) was shown to provide protection against the
development of MS symptoms (Sun, Czerkinsky, & Holmgren, 2012).
Type 1 diabetes (T1D) is a well-studied prototypic tissue specific autoimmune
disease resulting from auto-reactive lymphocyte destruction of the pancreatic islet
insulin-producing β-cells (Eisenbarth, 1986; J. C. Mbongue et al., 2015; Tisch &
McDevitt, 1996). Progressive loss of islet β-cell function leads to insulin deficiency and
high blood glucose levels (hyperglycemia). Increased cellular oxidative stress and
chronic inflammation generated by hyperglycemia can result in neural and circulatory
complications that lead to amputation, loss of kidney function, blindness, heart attack,
and stroke resulting in early mortality (Forbes & Cooper, 2013; J. C. Mbongue et al.,
2015; Melendez-Ramirez, Richards, & Cefalu, 2010). Linkage of CTB to insulin (CTBINS) provided a protective effect against the onset of type 1 diabetes in NOD mice
(Arakawa et al., 1998; Denes et al., 2005; Ploix et al., 1999). Initial oral immunization
experiments showed that feeding small amounts (2–20µg) of CTB-INS could effectively
suppress β-cell destruction and clinical diabetes in pre-diabetic NOD mice (Bergerot et
al., 1997; Denes et al., 2005; Denes et al., 2006). Initial recognition of the mechanism
underlying vaccine mediated immune suppression was based on CTB-INS induction of
CD4+ regulatory T cells (Tregs) in NOD mice (Meng, Wang, Shi, Jin, & Zhang, 2011).
Demonstrating the broad range of applications of this vaccine strategy for suppression of
autoimmunity, conjugation of CTB with islet auto-antigens including insulin and
glutamic acid decarboxylase (GAD) was shown to induce immunological tolerance
through the suppression of human DC maturation (Denes et al., 2005; Odumosu,
Nicholas, et al., 2011).
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Among the most promising therapeutics, immuno-suppressive vaccines were
shown to arrest autoimmunity in animals (Aspord & Thivolet, 2002; Bergerot et al.,
1997; Denes et al., 2005; Denes et al., 2006; Petrovsky, Silva, & Schatz, 2003). However,
vaccine efficacy in patients remains untested because their mode of action is unknown.
Due to variability of patient responses to individual vaccines, combinatorial vaccines may
provide the most effective form of treatment. Multicomponent vaccines composed of the
cholera toxin B subunit (CTB) linked to self-antigens were shown to prevent uveitis,
multiple sclerosis and type 1 diabetes in animal models of autoimmunity (Aspord &
Thivolet, 2002; Bergerot et al., 1997; Meng et al., 2011; Phipps et al., 2003; Stanford et
al., 2004) . Recent experiments showed that a CTB-insulin vaccine that induced tolerance
to diabetes autoantigens in humans is linked to inhibition of DC maturation (Odumosu,
Nicholas, et al., 2011; Odumosu, Payne, et al., 2011). While the mechanism responsible
for vaccine induced tolerance remains unknown, analysis of the vaccinated DC proteome
revealed dramatic up-regulation of the tryptophan catabolic enzyme indoleamine 2,3dioxygenase (IDO1)(J. C. Mbongue et al., 2015). Emphasizing the enzyme’s role in
autoimmunity, increased IDO degradation of tryptophan accompanied DC suppression of
arthritis, asthma, haemolytic anemia, multiple sclerosis, systemic lupus erythematosus
and type 1 diabetes (Ganguly, Haak, Sisirak, & Reizis, 2013; Kuroki et al., 2013;
Kwidzinski et al., 2003; Sakurai et al., 2002). Vaccine-induced IDO1 biosynthesis and
enzyme activity in human DCs suggest kynurenines may be important for vaccine
suppression of type 1 diabetes autoimmunity (Belladonna et al., 2009; Belladonna et al.,
2007; J. C. Mbongue et al., 2015; Pallotta et al., 2014; Zaher et al., 2011). Interestingly,
fusion of CTB to insulin was found to be essential for induction of IDO1 biosynthesis,
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suggesting vaccine signaling functions may be involved in suppression of DC activation
(J. C. Mbongue et al., 2015).

Significance of Studies
Autoimmune diseases are the second highest cause of chronic illness worldwide
and the primary cause of morbidity in women. Individual vaccine therapies for
suppression of autoimmunity are only partially effective, while multicomponent vaccines
promise greater therapeutic efficacy. Here, a chimeric fusion protein vaccine composed
of proinsulin linked to the cholera toxin B subunit adjuvant (CTB-INS) was selected for
prevention of the prototypic tissue specific autoimmune disease type 1 diabetes (T1D).
When insulin presenting dendritic cells (DCs) guide the differentiation of naïve insulin
reactive T cells into pro-inflammatory autoreactive effector cells that kill pancreatic
insulin producing β-cells, diabetes onset occurs. We have shown the CTB-INS vaccine
prevents diabetes in animals and generates immunological tolerance in human DCs.
Recent analysis of the vaccinated DC proteome revealed dramatic upregulation of
indoleamine 2, 3- dioxygenase (IDO), a tryptophan catabolic enzyme known to play a
dominant role in DC maintenance of immunological tolerance and suppression of
autoimmunity. Vaccine stimulated activation of NF-κB was shown to be necessary for
upregulation of dendritic cell IDO biosynthesis. Experiments described in this
dissertation will identify and confirm signaling mechanisms responsible for vaccine
upregulation of IDO biosynthesis and activity in normal DCs in vivo. Assessment of
chimeric vaccine modulation of human DC activation and guidance of T cell
differentiation will provide novel insights into vaccine suppression of T1D autoimmunity
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and will establish a basis for clinical application of chimeric vaccine strategies for
effective inhibition of diabetes autoimmunity in patients.
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Abstract
Dendritic cells (DC) interact with naïve T cells to regulate the delicate balance
between immunity and tolerance required to maintain immunological homeostasis. In this
study, immature human dendritic cells (iDC) were inoculated with a chimeric fusion
protein vaccine containing the pancreatic β-cell auto-antigen proinsulin linked to a
mucosal adjuvant the cholera toxin B subunit (CTB-INS). Proteomic analysis of vaccine
inoculated DCs revealed strong up-regulation of the tryptophan catabolic enzyme
indoleamine 2, 3-dioxygenase (IDO1). Increased biosynthesis of the immunosuppressive
enzyme was detected in DCs inoculated with the CTB-INS fusion protein but not in DCs
inoculated with proinsulin, CTB, or an unlinked combination of the two proteins.
Immunoblot and PCR analyses of vaccine treated DCs detected IDO1mRNA by 3 hours
and IDO1 protein synthesis by 6 hours after vaccine inoculation. Determination of IDO1
activity in vaccinated DCs by measurement of tryptophan degradation products
(kynurenines) showed increased tryptophan cleavage into N-formyl kynurenine.
Vaccination did not interfere with monocytes differentiation into DC, suggesting the
vaccine can function safely in the human immune system. Treatment of vaccinated DCs
with pharmacological NF-κB inhibitors ACHP or DHMEQ significantly inhibited IDO1
biosynthesis, suggesting a role for NF-κB signaling in vaccine up-regulation of dendritic
cell IDO1. Heat map analysis of the proteomic data revealed an overall down-regulation
of vaccinated DC functions, suggesting vaccine suppression of DC maturation. Together,
our experimental data indicate that CTB-INS vaccine induction of IDO1 biosynthesis in
human DCs may result in the inhibition of DC maturation generating a durable state of
immunological tolerance. Understanding how CTB-INS modulates IDO1 activity in
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Human DCs will facilitate vaccine efficacy and safety, moving this immunosuppressive
strategy closer to clinical applications for prevention of type 1 diabetes autoimmunity.

Introduction
The continued failure to find a cure for type 1 diabetes mellitus (T1D) is a prime
example of the urgent need for therapeutics that can safely deliver antigen specific
therapy for protection against tissue specific autoimmunity. Type 1 diabetes is a wellknown prototypic tissue specific autoimmune disease that results from auto-reactive
lymphocyte destruction of the pancreatic islet insulin-producing β-cells (Eisenbarth,
Flier, & Cahill, 1986; Tisch & McDevitt, 1996). The progressive loss of islet β-cell
function leads to insulin deficiency and high blood glucose levels (hyperglycemia).
Increased cellular oxidative stress and chronic inflammation generated by hyperglycemia
can result in neural and circulatory complications leading to amputation, loss of kidney
function, blindness, heart attack, and stroke resulting in early mortality (Forbes &
Cooper, 2013; Melendez-Ramirez, Richards, & Cefalu, 2010).
Dendritic cells, considered the most prominent subset of professional antigen
presenting cells (APC), are implicated in islet β-cell destruction (Allen et al., 2009;
Ganguly, Haak, Sisirak, & Reizis, 2013; Mbongue, Nicholas, Firek, & Langridge, 2014).
Through presentation of pancreatic β-cell antigens to naïve auto-reactive T helper cells,
DCs can guide their differentiation into effector Th1 and Th17 lymphocytes capable of
killing pancreatic β-cells(Atkinson & Maclaren, 1994; Tisch & McDevitt, 1996). Autoreactive CD4+ Th1 lymphocytes were shown to infiltrate pancreatic islets in non-obese
diabetic (NOD) mice and secrete the pro-inflammatory cytokines IFN-γ and IL-2
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(Pulendran et al., 2001; Pulendran et al., 1999). Dendritic cell regulation of T cell
morphogenesis is required for maintenance of immunological homeostasis.
However, in the presence of auto-reactive T cells, DC presentation of β-cell autoantigens may stimulate activation of these T cells and disrupt the delicate balance
between immune stimulation and immune suppression. The consequent imbalance can
result in development of chronic inflammation that may progress to T1D. Immunological
suppression strategies including combinatorial vaccines that link immune stimulatory
molecules (adjuvants) to antigens, have been developed to enhance vaccine efficacy
(Aspord & Thivolet, 2002; Bergerot et al., 1997). Prominent among adjuvants is the
cholera toxin B-subunit (CTB)(Odumosu, Nicholas, Yano, & Langridge, 2010). Linkage
of CTB to insulin (CTB-INS) results in a fusion protein that has been shown to have a
protective effect against the onset of T1D (Ploix et al., 1999). Initial oral immunization
experiments showed that feeding small amounts (2–20μg) of CTB-INS could effectively
suppress β-cell destruction and clinical diabetes in adult NOD mice (Bergerot et al.,
1997; Ploix et al., 1999). Initial recognition of the mechanism underlying vaccine
mediated immune suppression was based on CTB-INS induction of CD4+ regulatory T
cells (Tregs) in NOD mice(Meng, Wang, Shi, Jin, & Zhang, 2011). Prediabetic non-obese
diabetic (NOD) mice inoculated with CTB-INS fusion protein showed a decrease in
pancreatic islet inflammation (insulitis) characterized by a reduction in islet infiltration
with auto-reactive lymphocytes, increased proliferation of CD4+ regulatory T-cells, and
suppression of T1D onset (Denes, Fodor, & Langridge, 2013; Meng et al., 2011; Ploix et
al., 1999). In addition, increased expression of anti-inflammatory cytokines, such as
interleukin-4 (IL-4) and interleukin-10 (IL-10), were detected in pancreatic tissue isolated
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from treated animals (Ruhlman, Ahangari, Devine, Samsam, & Daniell, 2007). This work
provided a platform for more recent experiments that showed CTB-INS inhibition of
dendritic cell maturation can be identified by vaccine suppression of CD86 and CD80 costimulatory factor biosynthesis (Odumosu, Nicholas, Payne, & Langridge, 2011;
Odumosu, Payne, et al., 2011). Demonstrating the broad range of applications of this
vaccine strategy for suppression of autoimmunity, conjugation of CTB with islet autoantigens such as insulin and glutamic acid decarboxylase (GAD) was shown to induce
immunological tolerance through the suppression of DC maturation(Odumosu, Nicholas,
et al., 2011). Further, fusion of an uveitogenic HSP60 derived-peptide (aa 336–351) with
CTB resulted in significant protection against mucosally induced uveitis and Behcet’s
disease (Phipps et al., 2003; Stanford et al., 2004). Of further importance, fusion of CTB
with myelin oligodendrocyte glycoprotein (MOG) provided protection against the
development of multiple sclerosis (Sun, Czerkinsky, & Holmgren, 2012).
To date however, the molecular mechanism responsible for vaccine stimulation of
DC mediated immunosuppressive responses remains unknown. Thus, before effective
chimeric vaccine immune suppression strategies can be applied in clinical studies,
mechanisms underlying vaccine suppression of DC maturation must be identified and are
the subject of experiments described in this study.
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Materials and Methods
Construction of Bacterial Expression Vectors Containing the Cholera Toxin B
Subunit—Proinsulin Gene Fusion
A DNA sequence encoding 258bp of the human proinsulin gene (INS M12913.1)
was linked to the carboxyl-terminus of a DNA fragment (309bp) encoding the cholera
toxin B subunit gene (CTB U25679.1) to generate the fusion gene CTB-INS. Four GpGp
sequences were inserted between the two genes to promote molecular flexibility
(Arakawa, Chong, & Langridge, 1998). The CTB-INS fusion gene was cloned into E.
coli expression vector PBR-322 and the plasmid amplified in E. coli HB101 (Carter et al.,
2006).
To achieve high levels of transgene expression, the CTB-INS gene fusion was
subcloned into E. coli expression vector pRSET-A (Invitrogen, Carlsbad, CA) under
control of the bacteriophage T7 promoter(Odumosu, Payne, et al., 2011). The resultant
bacterial expression vector (pRSET-CTB-INS) contains an oligonucleotide encoding 6
contiguous histidines located immediately upstream of CTBINS to permit nickel affinity
column isolation of the recombinant fusion protein. Expression vector pRSET-CTB-INS
was transformed into the E. coli producer strain BL21 (DE3) pLysS (Invitrogen,
Carlsbad, CA) for production and isolation of milligram amounts of the CTB-INS protein
for further experiments(Carter et al., 2006).

Synthesis and Isolation of CTB-INS Fusion Protein
The E. coli strain BL21 transformed with pRSET-CTB-INS (Odumosu, Payne, et
al., 2011) was grown overnight at 37°C in a 2.0 ml Luria Broth (LB) shake culture
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containing 100 μg/ml ampicillin for selection of transformed cells. The lag phase cells
were transferred (1.0 ml) into 250 ml Luria Broth (LB) containing ampicillin (100 μg/ml)
and cultured at 37°C with gentle shaking. While still in log phase of growth, synthesis of
the CTB-INS protein was stimulated by addition of 2 mM fresh isopropyl β-D-1thiogalacto-pyranoside (IPTG) (Sigma Chemical Co. St. Louis, MO) to the bacterial
culture. After a 6-hour continued growth at 37°C, the bacterial culture was transferred
into 40 ml polystyrene Oakridge tubes and harvested by centrifugation in a Sorvall SA
600 rotor at 5,000 rpm for 10 minutes at 4°C with the brake off in a Sorvall RC5B
centrifuge. The soft cell pellets were resuspended in 1.0 ml of lysis buffer (100 mM
HEPES, protease inhibitor- Sigma Complete protease inhibitor cocktail, 5μl/ml DNAse
I), (Promega Inc.). The bacteria were disrupted by sonication with 3 × 10 seconds bursts
at a setting of 10Wwith a Sonic 60 Dismembrator (Fisher Sci. Sunnyvale, CA). The
CTB-INS protein was isolated and purified from the bacterial homogenate by nickel
affinity chromatography using a Maxwell Model 16 robotic protein purification system
(Promega Inc.) according to the protein isolation protocol provided by the manufacturer.
The recombinant protein product was isolated on Magnet-His Nickel-Iron alloy particles
with an affinity for the 6-HIS tag linked to the N terminus of the recombinant CTB-INS
fusion protein. To isolate the protein from the nickel-iron alloy particles, the Ni+ particles
were transferred into a clean tube and centrifuged at 2000 rpm on anEppendorf centrifuge
equipped with a 5417C rotor at room temperature. The beads were then washed three
times with 1.0 mL HEPES (100 mM). The protein was separated from the beads by resuspension in 1.0 mL Z- buffer (8M Urea, 100 mM NaCl, and 20 mM HEPES, pH 8.0).
The mixture was centrifuged for 5 minutes (10,000 rpm, 4°C). Imidazole and urea were
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removed from the protein by dialysis of the preparation against 2 × 1.0 Liter 10 mM
HEPES buffer (pH 7.5) for a total of 4 hours at 4°C. The purity of the CTB-INS protein
(23.4 kDa) was determined based on its electrophoretic mobility in a 12%
polyacrylamide gel in comparison with protein molecular weight standards (BioRad,
CA)(Odumosu, Payne, et al., 2011).

Ethics
Experiments on monocyte-derived DCs were performed ex-vivo, with aphaeresis
blood provided by the Life Stream Blood Bank (San Bernardino, CA) with Loma Linda
University IRB and blood donor consent. Blood donor information was anonymized and
de-identified prior to the study.

Isolation and Culture of Monocyte-derived Dendritic Cells from Human
Peripheral Blood
Monocyte-derived dendritic cells (MoDCs) were prepared from freshly collected
human peripheral blood cells isolated from aphaeresis filter cones obtained from the
LifeStream blood bank (San Bernardino, CA). The blood was incubated with a red blood
cell lysis buffer (3.0 mL Lysis Buffer/ mL of blood) (Boston Bioproducts), containing
8.3g/L NH4Cl, 1g/L KHCO3, and 1.8 mL 5% EDTA and centrifuged for 5 minutes at
1,500 rpm at 4°C in a Beckman Coulter Allegra X-15R centrifuge, equipped with a
SX4750 rotor. The CD14+ monocytes were obtained from the total lymphocyte fraction
by incubation with anti-CD14 antibodies bound to magnetic beads for 15 minutes at 4°C
(Miltenyi Biotech, Auburn, CA). The monocytes were separated from other immune cells

76

by binding to a magnetic MACS column followed by elution of all other leucocytes
(Miltenyi Biotech, Auburn, CA). The monocytes were eluted from the column and
cultured ranging from 2–9 × 106 cells/well in 6-well non-pyrogenic polystyrene culture
plates in RPMI 1640 culture medium (Mediatech Inc. Manassas, VA, USA), at 37°C in a
humidified atmosphere of 5% CO2 (Preprotech, Rocky Hill, NJ). The medium was
supplemented with 10% FBS, 1 mM glutamine, 100 U/ml penicillin, 100 μg/ml
streptomycin, 50 ng/ml human recombinant GMCSF, and 10 ng/ml human recombinant
IL-4 (ProSpec-Tany Techno- Gene, Rehovot Science Park, Israel). The monocyte cell
culture was fed at 2-day intervals by gentle replacement of 50% of the medium with fresh
culture medium. The cells were cultured for 6 days to allow differentiation into DCs prior
to vaccine treatment. The cells were observed by phase contrast microscopy to assess
dendrite formation, a marker for DC differentiation.

Vaccinated Dendritic Cell Sample Preparation and Mass Spectrometric
Analysis
After treatment with 10 μg/ml of CTB-INS, the dendritic cell pellet was lysed on
ice for 2 hours in radio-immunoprecipitation assay (RIPA) buffer (Santa Cruz
Biotechnology, CA) containing 1% Nonidet P40, PMSF (0.2 mM), and protease inhibitor
cocktail (Roche). The protein mixture was centrifuged at 10,000 rpm at 4°C for 15
minutes in a Beckman GS-15R centrifuge equipped with a F2402 rotor and the
supernatant transferred into a clean tube. The protein concentration in the supernatant
was determined by BCA Protein Assay (Thermo Scientific Pierce, Rockford, IL USA).
Approximately 60 μg of each protein sample was resuspended in 25mM
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triethylammonium bicarbonate buffer, pH 7.8. The protein was reduced by addition of10
mM DTT and incubated at 50°C for 30 minutes, followed by carboxymethylation
achieved by addition of 25 mM iodoacetamide and incubation of the mixture in the dark
for 1 hour. The proteins were precipitated by addition of 4 volumes of precooled (-20°C)
acetone and stored at -20°C overnight. The protein was pelleted at 14,000 rpm in the
Beckman GS-15R centrifuge for 10 minutes at 4°C and the supernatant discarded. The
protein pellet was dissolved in 25 mM triethylammonium bicarbonate buffer (100 μM
GTP, 100 μMGDP in 8 mM PIPES pH 6.8) and partially digested by trypsin (SigmaAldrich, St. Louis, MO) at a protein / trypsin enzyme ratio of 25:1 (by mass) for 10 hours
at 37°C. A Tandem Mass Tagging isobaric (TMT) Kit (Thermo-Fisher Scientific) was
used to label the peptides following the manufacturer’s recommended conditions. Each
TMT-labeled protein pool was acidified with 0.1% Formic Acid (FA) and fractionated by
strong cation-exchange (SCX) chromatography on a Toptip column (Poly LC, MD). For
fractionation, the column matrix was equilibrated with 0.1% FA in 20% acetonitrile
(ACN) to facilitate peptide binding. After collection of the flow-through volume, 1.0 mL
of each sub-fraction was eluted sequentially with 20% ACN, 0.05 MKCl, 0.2 MKCl, 0.5
MKCL, and 5% ammonium hydroxide in 20% ACN. Next, the fractions were dried under
vacuum to remove the ACN, reconstituted in 1% formic acid, and desalted using a Toptip
column with C18/hypercarb mixed materials (Poly LC, MD). The eluted peptides were
once again vacuum-dried, reconstituted in 30 μl of 0.1% FA, and subjected to LCMS/MS analysis. The peptides were separated by online reversed phase liquid
chromatography (RPLC) using an Easy-nLC equipped with an auto-sampler (Thermo
Scientific). A 10 cm, 75 μm id, 3-μm particle size, C18-A2 analytical column (Thermo
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Scientific) was used for the RPLC separations. Quantitation of the SCX fractionated
TMT-6 labeled peptides was carried out on the Thermo LTQ-Orbitrap Velos Pro mass
spectrometer. Approximately 2 μg of peptide sample was injected in the analytical
column. A pre-column (Thermo, 0.1 × 2 cm, 5 μm C18-A1) was brought in line with the
analytical column and a 250-min gradient (solvent A, 0.1% FA in water; solvent B, 0.1%
FA in ACN) from 5–30% solvent B was used for separating the peptides. The Orbitrap
mass analyzer was set to acquire data at R = 60,000 resolution for the parent full-scan
mass spectrum, followed by data-dependent high collision-energy dissociation (HCD)
MS/MS spectra for the top 12 most abundant ions acquired at R = 7500 resolution.

Dendritic Cell Proteome Data Analysis
Vaccinated DC proteins were identified and quantified by analysis with the
Proteome Discoverer 1.4 platform (Thermo) and the Mascot search engine (Mascot
Darmon 2.2.2; Matrix Science, London, UK) employing the International Protein Index
(IPI) Homo sapiens database (version 3.73, June 2010, containing 89739 entries). Mascot
searching parameters were used as follows: Carbamidomethylation of cysteine and TMT6 modification of the peptide N-terminus and lysine were set as fixed modifications and
oxidation of methionine and deamination of asparagine and glutamine were set as
variable modifications. Trypsin was the protease selected and preparations containing up
to two missed cleavages were used. Mass tolerance for the precursor ions was 10 ppm
and for the MS/MS 0.2 Da. The peptides were filtered for a maximum false discovery
rate of 1%. At least one unique peptide with a posterior error probability of less than 0.05
was accepted for quantification using the grouped TMT-reporter ions and proteins.
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Ingenuity Pathway Analysis of the Vaccinated DC Proteome
The Ingenuity Pathway Analysis program (IPA) is an intuitive web-based
application for rapid and accurate analysis and interpretation of the biological meaning in
genomic and proteomic data. Predicted protein-protein interaction networks and
canonical pathways were generated from the mass spectrometer data analysis of dendritic
cell proteins isolated before and after vaccine inoculation by IPA Software (Ingenuity
Systems, www.ingenuity.com) (Qiagen, USA). Analysis of networks and pathways were
made using log2 fold-changes and p-values between two-group comparisons. The ratios
of significant protein expression levels were determined at r = 1.25.

Determination of Vaccinated Dendritic Cell IDO1 mRNA Expression
Immature DCs were incubated with or without CTB-INS (10 μg/ml) and ACHP
(500 nM) in culture medium for 1, 3, 6, 9, 12, 24 hours. The cells were lysed using the
RNA-STAT 60 RNA isolation protocol (Tel-Test, Friendswood, TX). Indoleamine
dioxygenase cDNA was synthesized from 1 to 2 μg total RNA using the SydQuanti First
Strand cDNA Synthesis Kit (Syd Labs, Malden, MA) according to manufacturers’
instructions. Dendritic cell IDO1 mRNA (NM_002164.5) was quantified relative to βactin using the following primers: IDO1 forward, 5’-TCTGGCCAGCTTCGAGAAAG3’ IDO1 reverse, 5’-AGAACTAGACGTGCAAGGCG-3’; β-actin forward, 5’GCATTGCTTTCGTGTAAATTATGT-3’; β- actin reverse, 5’ACCAAAAGCCTTCATACATCTCA-3’. Quantitative reverse transcriptase-polymerase
chain reaction (RT-PCR) was initiated by SYBR Green JumpStart Taq ReadyMix
(BioRad) according to the manufacturer’s instructions. The PCR reactions were
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performed in a CFX-96 BioRad C- 1000 thermal cycler (BioRad Laboratories, Hercules,
CA). Analysis of the data was completed with BioRad CFX manager software version
2.1 (BioRad Laboratories). All the PCR measurements were performed in triplicate and
validated when the difference in threshold cycle (Ct) between the 3 measurements was <
0.3. The ratio of gene of interest/housekeeping gene was calculated according to the
formula: ratio = 2-dCt (dCt = mean Ct gene—mean Ct housekeeping). Dendritic Cell
synthesized β-actin was used to normalize for the presence of IDO1 mRNA. To establish
statistical significance, the experiment was performed five times per subject DC
collection.

Detection of IDO1 Protein Synthesis in Vaccinated Dendritic Cells
Approximately 2–9 × 106 monocyte-derived DCs generated from each of several
subjects were treated with CTB-INS (10 μg/ml), CTB (5μg/ml) (Sigma-Aldrich), human
insulin (5μg/ml) (Sigma-Aldrich), recombinant human E. coli-derived proinsulin (5
μg/ml) (R&D Systems) and c-peptide (2 μg/ml) (Sigma-Aldrich). The inoculated DCs
were lysed in buffer C (20 mM HEPES, 0.42 M KCl, 26% Glycerol, 0.1 mM EDTA, 5
mM MgCl2, 0.2% NP40) containing a tablet of complete protease inhibitor (Roche,
Basel, Switzerland) according to the manufacturer instruction. At least 50 μg of protein
isolated from the total DC lysate was separated by electrophoresis on a 12%
polyacrylamide gel (SDS-PAGE). After transfer of the separated proteins to
polyvinylidene difluoride (PVDF) membranes (Millipore, Temecula, CA). The presence
of IDO1 protein (NP_002155.1) was detected by incubation of the blot for 12 hours at 4o
C with an anti-IDO1 rabbit monoclonal primary antibody (Cat. 04–1056, clone
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EPR1230Y) (Millipore, Temecula, CA). For signal detection, the blot was washed 3
times with PBST and incubated for 2 hours at room temperature in the presence of a
monoclonal anti-rabbit IgG γ-chain specific alkaline phosphatase conjugated secondary
antibody (Cat. A-2556, clone RG-96) (Sigma-Aldrich). The blots were washed 3 times in
PBST (1X PBS, 0.02% tween 20, pH 7.4) and were incubated in 200 μL of Novex AP
chemiluminescent substrate (Invitrogen) for 5 minutes. The chemiluminescent labeled
blot was exposed to x-ray film (Kodak X-Omat) for 3 minutes. The IDO signal intensity
was quantified via Image J software v. 1.48h. (Image J, NIH).

Flow Cytometric Analysis of Vaccinated Dendritic Cells
Peripheral blood monocytes were plated in 96 well plates in RPMI 1640 culture
medium containing 10% FBS and divided into two experimental groups. One group was
inoculated with CTB-INS (10μg/ml) and GMCSF (50ng/ml) and IL-4 (10 ng/ml) and the
second group was inoculated with GMCSF and IL-4 without CTB-INS. The treated cells
were cultured for 2, 4 and 6 days. After incubation, the differentiating DCs were stained
for flow cytometry with the following antibodies: anti-CD14 FITC (Miltenyi), anti-CD86
PE, anti-HLA-DR PerCP (Beckton
Dickenson), anti-CD11c PE-Cy7 (Biolegend) and anti CD83 APC (Miltenyi). The
differentiating cells were identified by flow cytometry (MacsQuant, Miltenyi Inc) and the
data analyzed using FlowJo software v.7.6 (Treestar).
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Pharmacological Inhibitors of NF-κB Activation
The NF-κB inhibitor dehydroxymethylepoxyquinomicin (DHMEQ) was provided
by the laboratory of Dr. Kazuo Umezawa, Department of Molecular Target Medicine
Screening, Aichi Medical University, School of Medicine, Nagakute, Aichi 480–1195,
Japan. DHMEQ was shown to successfully inactivate NF-κB p50/p65, and p52/RelB
subunits (Umezawa, 2006). The DHMEQ was dissolved in DMSO at a concentration of
3.0 mg/ml and administered to CTB-INS vaccinated dendritic cell cultures at a final
concentration of 3μg DHMEQ/ml culture medium. The cells were incubated in culture
medium containing the inhibitor for 24 hours at 37°C. The Iκβ kinase inhibitor, 2-Amino6-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-4-(4- piperidinyl)-3-pyridinecarbonitrile
(ACHP), (Tocris Bioscience, Bristol, UK), was dissolved in DMSO at a concentration of
25 mM and added to the culture to a final concentration of 500 nM. ACHP is a selective
inhibitor for IKKα and IKKβ (IC50 values are 8.5 and 250 nM for IKKβ and IKKα
respectively). ACHP was shown to inhibit DNA binding activity of NF-κB and to block
NF-κB pathways in multiple myeloma cell lines (Sanda et al., 2005).

Determination of IDO1 Enzymatic Activity in Vaccinated Dendritic Cells
Approximately 3–9 × 106 monocyte-derived CD14- HLADR+ dendritic cells
from three subjects were cultured in RPMI medium + 10% fetal bovine serum in the
presence or absence of CTB-INS fusion protein (10 μg/ml) at 37°C for 24 hours in 8.8
cm Nunc cell culture plates (cat. 150318) (Thermo Scientific, Waltham, MA, USA). The
cells were harvested by scraping the plate with a rubber policeman. The DCs were
washed twice with PBS and centrifuged at 524 × g in a Beckman Coulter Allegra X-15R
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centrifuge at 4°C and the pellet re-suspended in 0.5 ml of ice cold PBS. The cells were
lysed by incubation in lysis buffer C containing 20 mM HEPES, pH = 7.8, 0.42 MKCl,
26% Glycerol, 0.1 mM EDTA, 5mM MgCl2, 0.2% NP40 and a Roche complete protease
inhibitor cocktail. The protein concentration in the supernatant was measured by
Bradford assay (Salahshoor et al., 2013) with BSA as the standard, to permit assessment
of equal protein concentrations among homogenate samples and to reduce sample bias.
To measure changes in kynurenine concentrations following vaccine inoculation, the
standard kynurenine assay mixture (100 μl total volume) contained 50 mM potassium
phosphate buffer (pH 6.5), 20 mM ascorbate, 10μMmethylene blue, 100 μg/ml of
catalase and an appropriate amount of the cellular extract (10–100 μL) containing equal
total protein concentration between samples. The reaction was initiated by adding the
substrate L-tryptophan (400 μM) and terminated after 1 hour incubation at 37°C. A
volume of 20 μL of 30% trichloroacetic acid was added to the mixture followed by
incubation of the mixture at 50°C for 30 minutes to terminate the reaction and to
hydrolyze the N-formyl kynurenine cleaved by IDO1 to L-kynurenine (Takikawa,
Kuroiwa, Yamazaki, & Kido, 1988). After centrifugation, the supernatants were divided
into 2 experimental groups. The first group was treated with 100 μM final concentration
of the IDO1 inhibitor L-1- methyl-tryptophan (L-1-MT) and the other was left untreated.
The optical density of the samples was measured at 490 nm. The absorbance values were
plotted against a standard curve of defined kynurenine amounts (0–100 μM). Kynurenine
determinations were repeated 3 times for each subject from a total of 3 subjects. After
comparison with the standard curve of kynurenine concentrations, the data were
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presented as IDO1 activity. One unit of the enzyme activity was defined as the amount of
enzyme that produced 1 nmol of kynurenine/h.

Statistical Analysis
All the quantitative data of this study were expressed as the mean ± SD and
statistical analysis was conducted using GraphPad Prism software v.6.01 (La Jolla, CA).
Comparisons between appropriate groups were performed with paired Student’s t-test and
probability p <0.05 was considered to indicate a statistically significant difference. Each
experiment was repeated at least twice to assess the level of reproducibility.

Monocyte and Dendritic Cell Viability in the Presence of IDO1 Inhibitors
Monocyte derived dendritic cells were treated with ACHP (500 nM) and DHMEQ (3
μg/ml) for 24 hours and stained with annexin V and propidium iodide (PI) to determine
cell viability. The percentage of DCs negative for annexin V and PI was obtained by flow
cytometry analysis.

Results
Dendritic cells were both treated with 10μg/ml of CTB-INS or PBS for 24 hours
and lysed. To determine the effects of CTB-INS vaccination on the DC proteome, we
employed Orbitrap mass spectrometry to identify and quantify vaccine regulated proteins
and Ingenuity Pathway Analysis (IPA) algorithms, to assess their role in signaling or
metabolic functions in vaccinated DCs. A total of 845 proteins were identified in
unvaccinated DCs and 654 proteins were identified as unique and significantly up or
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down regulated in CTB-INS vaccinated DCs. About 131 proteins were detected as
common in both vaccinated and unvaccinated DCs (Figure 6A). Signaling pathways
identified by IPA that correlated with changes in protein expression in vaccinated DCs
were arranged by decreasing—log (p-values) (Figure 6B). Identified among these
pathways were 2 types of tryptophan degradation pathways, namely the tryptophan
degradation pathways III and X (Belladonna et al., 2007). Ingenuity pathway analysis of
the ratios of up and down-regulated proteins over the total number of proteins in each DC
metabolic or signaling pathway showed that the tryptophan degradation pathway, the aryl
hydrocarbon receptor signaling pathway and the dopamine degradation pathway were
significantly up-regulated in the presence of the vaccine (Figure 6B).
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Figure 6. Mass spectrometric identification of the CTB-INS vaccinated DC proteome. (A)
Venn diagram of significantly up or down regulated proteins in human monocyte derived
dendritic cells inoculated with CTB-INS in comparison with monocytes as the baseline. A
total of 845 proteins were identified in untreated DCs and 654 up and down-regulated
proteins were unique in CTB-INS treated DCs, while 131 proteins were common to both
treated and untreated DCs. (B) Canonical, metabolic and signaling pathways that correlate
with changes in protein expression in CTB-INS vaccinated dendritic cells identified by
IPA program analysis. The threshold line represents the value at which statistical
significance is reported. The grey line connects the ratios between the number of up and
down-regulated proteins over the total number of proteins identified in each of the
pathways shown.
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The effect of CTB-INS vaccination on changes in DC cellular functions including
protein synthesis, maturation, and the immune response are presented graphically in the
heat map (Figure. 7A). Dendritic cell functions (shown as z-scores), are displayed as upregulated (red bands), down-regulated (green bands) or insignificantly changed (yellow
bands), following DC inoculation with the vaccine. Dendritic cell functions identified by
IPA that correlate with bands in the heat map are labeled as numbers to the right of the
map. Functions associated with mechanisms leading to increased dendritic cell
maturation, such as the immune responses of dendritic cells, cell movement, and cell
migration, were found to be significantly down-regulated in CTB-INS treated dendritic
cells (Faure-Andre et al., 2008; Palucka, Banchereau, & Mellman, 2010). Integrin
associated protein (CD47), involved in a wide range of inflammatory cellular processes
including activation, proliferation, migration and immune responses(Sick et al., 2012),
was also found to be markedly down-regulated (Table 1). The dataset used to generate
the heat map was analyzed by principal component (PC) analysis in order to identify the
extent of cellular function correlation with CTB-INS treatment (Figure 7B). As predicted
from the heat map, CTB-INS vaccination induced distinct cellular functions in DCs that
correlated with a change toward immune suppression which were absent from
unvaccinated DCs. Cellular functions up-regulated in CTB-INS (+) treated DCs include
RNA splicing and processing of mRNA which appear on the plot near the arrowhead of
the CTB-INS (+) vector, indicating a high level of correlation with DC vaccination.
Alternatively, pro-inflammatory cellular functions such as infection of cells, are strongly
down-regulated in CTB-INS (+) DCs, and are located near the arrowhead of the CTBINS (-) vector.
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Figure 7. CTB-INS vaccine induced changes in DC cellular functions. (A) Heat map
representing cellular functions (z-scores*) identified in vaccinated dendritic cells. Red
bands indicate up-regulated cellular functions, yellow bands indicate no change in function
and green bands indicate down-regulated cellular functions. (B) Principal component (PC)
analysis of dendritic cell functions, z-scores. The Bi-plot correlates dendritic cell functions
(+/-) vaccine treatments as indicated by the proximity of individual DC functions
(numbers) to either vector arrowhead [a = CTB-INS (-), b = CTB-INS (+)]. Numbers
further from the mean in the direction of the vector exhibit an increased correlation of the
DC function with a or b. Example: Function #12 is highly correlated with unvaccinated
DCs, [CTB-INS (-)] and Function #2 is poorly correlated with vaccinated DCs, [CTB-INS
(+)]. Zero (0) is the weighted mean of the multivariate dataset. The values on the (x; y) axis
represent (+/-) deviation from the mean of the dataset (0). (*z-score = statistical
measurement of a score’s relationship to the mean in a group of scores. A z-score of 0
means the score is the same as the mean. A z-score can also be positive or negative,
indicating whether it is above or below the mean and by how many standard deviations.)
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Table 1. Effect of CTB-INS on dendritic cell proteins associated with maturation and activation.
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Table 2. Effect of CTB-INS on proteins associated with type 1 diabetes onset.
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To address how CTB-INS interacts with DCs to suppress T1D, we used the IPA
program to identify up or down-regulated DC proteins that might be associated with DC
activation (maturation) and the onset of T1D (Tables 1 and 2). Among these proteins,
indoleamine 2, 3- dioxygenase (IDO1), the first enzyme of the tryptophan degradation
pathway, was found to be significantly up-regulated. Dendritic cells were incubated in the
presence or absence of CTB-INS for 24 hours. Orbitrap mass spectrometry was used to
identify the DC proteins and their relative abundance. Molecules associated with the up
or down- regulation of dendritic cell maturation were identified by IPA program analysis.
The up and down arrows indicate proteins significantly up or downregulated during CTBINS suppression of DC maturation and activation.
Dendritic cells were incubated in the presence or absence of CTB-INS for 24 hrs.
Orbitrap mass spectrometry was used to identify DC proteins and their relative
abundance. Molecules associated with the onset of T1D were identified by IPA program
analysis. The arrows indicate significant down-regulation of proteins involved in insulindependent diabetes (T1D) onset by treatment with the CTB-INS vaccine.
To confirm the mass spectrometry data, we assessed CTB-INS induced upregulation of IDO1 in DCs by immunoblotting and found that DCs treated for 24 hours
with CTB-INS (10μg/ml) showed a significant increase in IDO1 biosynthesis (Figure
8A). To determine the specificity of CTB-INS fusion protein for induction of IDO1,
dendritic cells were incubated with CTB, insulin, proinsulin, c-peptide, a combination of
both CTB and insulin, and CTB-INS fusion protein for 24 hours followed by immunoblot
analysis. Unlike CTB-INS, none of the vaccine components delivered alone or together
induced IDO1 biosynthesis (Figure 8B). The CTB-INS fusion protein induced detectable
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levels of IDO1 in DCs as early as 3–6 hours after treatment and IDO1 RNA levels as
early as 3 hours. (Figure 7C-E). These results clearly demonstrated CTB-INS-induced
IDO1 is enzymatically active in conversion of L-tryptophan into L-kynurenine.
Kynurenine biosynthesis was arrested by 100 μM of the IDO1 inhibitor L-1- methyltryptophan (1-MT) as shown in Figure 8F-G.
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Figure 8. Vaccine induction of IDO1 biosynthesis in dendritic cells. (A) Immunoblot
detection of IDO1 protein synthesis in human DCs in the presence of CTB-INS. (B)
Immunoblot analysis of IDO1 up-regulation in DCs inoculated with all components of the
CTB-INS fusion protein including insulin C-peptide. The images are representative of five
subjects. (C) Reverse transcriptase polymerase chain reaction (RT-PCR) for assessment of
IDO1 mRNA expression in a time dependent manner from DCs incubated with and without
CTB-INS. RNA (2 μg). The cDNA samples were used as templates for PCR amplification.
The DNA amplification products were visualized on X-ray film after electrophoresis in
2.0% agarose gels. Lane M: 100 bps DNA ladder marker (Gibco); lane NC: negative
control RNA after treatment with DNase I from DCs as template; lane 0: cDNA from DCs
without CTB-INS inoculation (-); lanes 1, 3, 6, 9, 12 and 24: cDNA from time-dependent
DCs incubated with CTB-INS (+). A β-actin gene was used as an internal standard in RTPCR. The image is representative of 3 different subjects. (D, E) Immunoblot of a time
course of IDO1 expression in DCs after inoculation with CTB-INS (10μg/mL). Cell
samples were harvested at 0, 3, 6, 8, 12 and 24 hours after vaccine inoculation. The data is
representative of 6 different subject samples. (Shapes on Panel E represent different
subjects). (F, G) Assessment of vaccine induced IDO1 activity and L-1-methyl-Ltryptophan (L-1-MT) inhibition of IDO1 activity in vaccinated DCs identified by ELISA.
Top wells in the plate (F), show the production of tryptophan degradation products
(kynurenines) in vaccinated DCs. Bottom wells show the inhibition of IDO1 kynurenine
biosynthesis (absence of yellow color), in vaccinated DCs treated with L-1-MT (bottom
wells). The data was compared for significance using a paired t-test, p = 0.018.
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Based on the observation that CD40 ligand (CD40L) induces IDO1 biosynthesis
through NF- κB signaling in human DCs (Tas et al., 2007), we investigated the role of
NF-κB signaling pathway involvement in CTB-INS induced IDO1 biosynthesis. To
assess the requirement for NF-κB in vaccine up-regulation of IDO1 we attempted to
block vaccine stimulated IDO1 biosynthesis in DCs with two different NF-κB
pharmacological inhibitors, ACHP and DHMEQ. Assessment of DC viability following
ACHP and DHMEQ treatment indicated both inhibitors were not toxic to DCs (Figure
9A). Immature dendritic cells were incubated with CTB-INS +/- the NF-κB inhibitor
ACHP. The levels of IDO1 mRNA were found to be significantly increased in vaccinated
DCs while addition of ACHP to vaccinated DCs completely inhibited IDO1 transcription
(Figure 9B-C). Correspondingly, IDO1 protein levels were significantly higher in cells
inoculated with CTB-INS than in DCs incubated for 24 hours with CTB-INS + either
ACHP or DHMEQ. (Figure 8D-G). Both DHMEQ and ACHP were shown to be equally
effective in blocking DC biosynthesis of IDO1 (Figure 9H). The mass spectrometry
proteome data from vaccine treated DCs was compared with a network of upstream
regulators of IDO1 identified by IPA. The experimental results indicated that vaccine
induced expression of IDO1 mRNA may be dependent not only on NF-κB, but also on
AhR and STAT1 transcriptional activators as well as vaccine-induced down-regulation of
the tyrosine kinase binding protein (TYROBP)(Grohmann et al., 2003; Muller,
DuHadaway, Donover, Sutanto-Ward, & Prendergast, 2005) (Figure 10).
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Figure 9. ACHP and DHMEQ inhibitors of NF-κB block CTB-INS induced IDO1
biosynthesis. (A) Dendritic cell viability was measured by determination of the percentage
of DCs negative for annexin V and propidium iodide following treatment with ACHP (500
nM) and DHMEQ (3μg/ml). The measurement of DC viability shows vaccinated DCs are
unaffected by treatment with the inhibitors. (B, C) Agarose gel electrophoresis and graphic
representation showing changes in IDO1 mRNA levels in DCs from three representative
subjects determined by qRT-PCR after 3 hours incubation of subject monocyte derived
DCs with CTB-INS (10 μg/mL) or CTB-INS and ACHP. Statistical significance (p<0.05)
was achieved by analysis of a total of 5 subjects. (The vehicle used is the DMSO solvent
in which ACHP and DHMEQ are dissolved). (D, E) Immunoblot and graphic
representation of the fold change in IDO protein synthesized 24hrs after vaccine
inoculation of subjects DCs inoculated with CTB-INS +/- ACHP. The experimental data
was collected from five normal subjects, although only one representative subject is shown.
Statistical significance between vaccine treated and vaccine + ACHP treated groups was
measured by paired Student’s t test, (p = 0.0273). (F, G) Immunoblot and graphic
representation of the fold change in IDO1 protein synthesized in subject DCs following
inoculation with CTB-INS with and without DHMEQ. While experimental data was
collected from five normal subjects, only two are shown to highlight the variability in IDO1
levels observed among subjects. Statistical significance was measured by paired Student’s
t test (p = 0.017). (H) Graphic representation showing the relative efficacy of ACHP and
DHMEQ inhibitors for blocking NF-κB induction of IDO1 biosynthesis.
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Figure 10. Diagram of upstream signals that regulate IDO1 biosynthesis in CTB-INS
vaccinated human DCs. Signaling pathways involved in vaccine up-regulation of IDO1
biosynthesis in human DCs were identified by Ingenuity Pathway analysis of proteins
detected in vaccinated DCs by mass spectrometer analysis. (Red: up-regulation of the
protein, Green: down-regulation of the protein, Grey: protein levels unchanged, White:
Undetected). Based on calculations generated from the mass spectrometry data, the IPA
program indicates the vaccine up-regulates the aryl hydrocarbon receptor (AhR) signal
transduction pathways and down regulates TYROBP to increase IDO biosynthesis. NFκB1: is the P105 precursor subunit of NF-κB which is cleaved to generate the P50 subunit
of the canonical NF-κB transcriptional activator protein, located in the cytoplasm. NF-κB2:
is the P100 subunit of non-canonical NF-κB, cleaved to generate the p52 subunit, located
in the cytoplasm. CYP1B1: Cytochrome P450, Family 1, Subfamily B, polypeptide 1, cell
location-Cytoplasm (up-regulated, 1.540 fold). AhR: Aryl Hydrocarbon Receptor, located
in the cytosol and nucleus, (up-regulated, 1.270 fold). COMMD1: Copper metabolism
(Murr-1) domain containing 1, located in cytosol and nucleus, (down-regulated 2.748 fold).
RAC-1: ras-related C3 botulinum toxin substrate 1. Located in the inner plasma membrane,
(down-regulated 1,895 fold.) JUN: JUN proto-oncogene, location, nucleus, (up-regulated,
1.584 fold.) EZH2: Enhancer of Zeste homolog 2, a histone methyltransferase that forms
part of the polycomb repressive complex-2, located in the nucleus, (up-regulated 7.244
fold). TYROBP: Tyrosine kinase binding protein, located in the plasma membrane (downregulated 1.982 fold). IDO1: Indoleamine 2, 3 dioxygenase, located in the cytoplasm, (upregulated 1.556 fold). Fold regulation values presented represent the average of 7 subjects.
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Despite phenotypic and functional differences based on their origin, maturation stage,
and culture conditions, DCs display common features among their subsets. These features
include similar morphology, high density of membrane HLA class II co-stimulatory
molecules, low phagocytic activity, and a strong capacity for antigen uptake and
presentation to T lymphocytes(Caux, Liu, & Banchereau, 1995; Chapuis et al., 1997).
Under normal conditions of immunological homeostasis, monocytes are more numerous
than DCs and can differentiate into dendritic cells (Ziegler-Heitbrock et al., 2010). To
assess vaccine safety for clinical applications, we examined potential detrimental effects
of vaccine inoculation on the differentiation of monocytes into dendritic cells (Figure 11).
Peripheral blood monocytes were isolated and inoculated with CTB-INS plus GM-CSF
and IL-4 in one experimental group and another group of monocytes were inoculated
with only GM-CSF and IL-4 only. Both experimental groups were cultured for 2, 4 and 6
days post inoculation. The disappearance of the CD14 monocyte markers and appearance
of the dendritic cell MHC Class II HLA-DR markers were monitored during DC
differentiation. The morphogenesis of monocytes into dendritic cells was not impeded by
inoculation with CTB-INS and the levels of DC maturation markers CD86 and CD83
measured by flow cytometry were lower than the controls in monocyte cultures
inoculated with CTB-INS (Fig. 6C-D). The time required for differentiation from
monocytes to DCs was not altered by inoculation with CTB-INS. In addition, DCs treated
with the vaccine showed a modulation of proteins involved in the suppression of DC
maturation and activation (Table 1) along with down regulation of many proteins
involved in the onset of type 1 diabetes (Table 2).
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Figure 11. CTB-INS vaccination of monocytes does not interfere with dendritic cell
differentiation. Flow cytometric analysis of vaccinated monocyte differentiation into
dendritic cells. (A) The CD14 monocyte marker becomes progressively less positive
(number inside the box (gate), as DC differentiation proceeds in the presence of the CTBINS fusion protein. (B) The HLA-DR marker indicative of antigen presenting cell DC
morphogenesis increases as dendritic cell differentiation progresses in the presence of
CTB-INS. (C) The co-stimulatory factor marker for DC maturation CD86 is observed to
decrease with time in vaccinated DCs in comparison with background levels. (D) With
time after inoculation with CTB-INS, the dendritic cell marker CD83 indicative of DC
maturation decreases in comparison with unvaccinated DC background levels.
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Figure 12: IDO is required for CTB-INS Suppression of DC activation and Maturation.
Diagram showing the effect of siIDO on CD11c, CD83 and CD86 mean fluorescence
intensity (MFI). Experiment performed on three different subjects.
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Discussion
Our laboratory and others have previously demonstrated the phenomenon of
suppression of insulitis and autoimmune diabetes in CTB-INS vaccinated NOD mice
(Bergerot et al., 1997; Denes et al., 2013). However, the cellular and molecular
mechanisms underlying CTB-INS modulation of dendritic cell mediated immune
suppression of T1D remain poorly understood. Because DCs are arguably the most
important population of antigen presenting cells involved in the induction of
inflammatory and auto-reactive T cell morphogenesis, we investigated the effects of
CTB-INS on human immature dendritic cell activation (maturation) ex vivo and
attempted to correlate the experimental data with findings obtained from earlier NOD
mice studies.
Analysis of the mass spectrometry data by IPA algorithms indicated that a
significant number of dendritic cell proteins (654) were uniquely modulated either
negatively or positively by vaccination with CTB-INS (Figure 6A). Metabolic or
signaling pathways including two tryptophan degradation pathways (IDO, INDO), the
aryl hydrocarbon receptor (AhR) and the dopamine degradation pathway (DA),
demonstrated a significantly high ratio of vaccine modulated proteins (Figure 6B).
Dendritic cells inoculated with the CTB-INS fusion protein demonstrated a
general reduction in their metabolism and immune functions (Figure 7). Dendritic cell
functions identified by IPA that showed a high number of pro-inflammatory functions
involved with DC activity, movement and migration were down-regulated by the vaccine.
Inflammatory functions such as infection, migration and proliferation of dendritic cells
(Figure 7B, Functions 12, 17, and 23) were found near the arrowhead of the CTB-INS (-)
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vector. These results suggest CTB-INS may exert an anti-inflammatory function on DCs.
Alternatively, dendritic cell functions shown to be up-regulated such as RNA splicing
and processing of mRNA (Figure 7B, functions 21, 22 and 27) were located near the
arrowhead of the CTB-INS (+) vector on the bi-plot (Figure 7B), suggesting a high level
of IDO1 mRNA processing induced by the vaccine. Together, these experimental
findings suggest the vaccine induces changes in dendritic cell functions that favor
maintenance of immunological tolerance.
Encoded by the IDO1 gene, indoleamine 2, 3-dioxygenase is the rate-limiting
catabolic enzyme responsible for initiating the degradation of L-tryptophan (L-Trp) to Nformyl kynurenine and its downstream degradation products (Figure 3)(Najfeld,
Menninger, Muhleman, Comings, & Gupta, 1993). Additional experimental findings
showed that in addition to tryptophan starvation of DCs, paracrine effects of secreted
kynurenine tryptophan degradation products may contribute to DC tolerogenesis through
initiation of inflammatory T cell apoptosis (Belladonna et al., 2007; Fallarino et al.,
2002). Therefore, part of the mechanism responsible for IDO1 stimulated immune
suppression may reside in the inhibitory or stimulatory effects of kynurenines on T cell,
regulatory T cell (Treg) and natural killer (NK) cell proliferation (Frumento et al., 2002;
Mezrich et al., 2010). Further, both depletion of dendritic cell tryptophan coupled with
the immunosuppressive action of kynurenine degradation products on T cell functions,
including activation of NF-κB and additional transcription factors such as AhR, may
contribute to the broad and powerful immunosuppressive actions of IDO1(Fallarino et al.,
2006). It has recently been shown that the immunosuppressive effect of IDO1 requires
both its enzymatic and signaling functions in NOD mice (Pallotta et al., 2014; Pallotta et
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al., 2011). In these studies conducted by Pallotta et al., IDO1 signaling activity was
triggered in plasmacytoid dendritic cells (pDCs) by transforming growth factor-β (TGFβ), through the non-canonical NF-κB pathway to induce long-lasting IDO1 expression
and autocrine TGF-β production in a positive feedback loop. Additionally, IDO1
expression and catalytic function were found defective in pDCs from NOD mice. Our
experimental data shows that CTB-INS induced IDO1 biosynthesis in DCs results in the
production of L-kynurenine (Figure 8). Supporting these experimental results, dendritic
cells with high IDO1 expression levels were shown to generate increased tryptophan
catabolites such as L-kynurenine, 3-hydroxykynurenine and 3-hydroxyanthranilic acid
and were able to suppress allogeneic T-cell proliferation irreversibly in vitro(Frumento et
al., 2002).
To determine the specificity of CTB-INS fusion protein for stimulating IDO1
biosynthesis, it was necessary to test the fusion protein components for their ability to upregulate IDO1 in monocyte-derived DCs. The lack in the induction of IDO1 expression
by CTB corroborated the previous findings of Slavica et al.(Slavica et al., 2012).
Interestingly, both insulin, proinsulin and the linking peptide (c-peptide) were unable to
induce detectable levels of IDO1, suggesting that up-regulation of IDO1 biosynthesis is
dependent on the fusion of CTB to the auto-antigen (Figure 8B).
In addition to showing that CTB-INS increases IDO1 mRNA and protein levels
(Figure 9B), we investigated the nature of signaling pathways required for CTB-INS
induction of IDO1. Inhibition of IDO1 biosynthesis by ACHP and DHMEQ suggests that
CTB-INS induction of IDO1 occurs through blocking the canonical and/or the noncanonical NF-κB signaling pathways (Figure 9). The specific involvement of the non-
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canonical NF-κB pathways in CTB-INS induction of IDO1 has yet to be elucidated in the
following chapter of this manuscript. Ingenuity pathway analysis of the mass
spectrometry data from vaccine treated DCs in comparison with a network of upstream
regulators of IDO1 revealed the aryl hydrocarbon receptor (AhR) transcriptional activator
protein to be a potential alternative mechanism that might cooperate with NF-κB for upregulation of IDO1 (Figure 10). Recently AhR was shown to be required for induction of
IDO1 biosynthesis (Nguyen et al., 2010). More recently RelB was shown to bind to AhR
suggesting a cooperative effect in IDO1 up-regulation by the two transcriptional
activators (Vogel et al., 2013). Additionally, N-formyl kynurenine, the first breakdown
product in the IDO1-dependent tryptophan degradation pathway was shown to activate
AhR leading to AhR-dependent Treg generation (Mezrich et al., 2010).
Demonstrating the immunosuppressive function of CTB-INS, the tyrosine kinase
binding protein (TYROBP) is involved in the down-regulation of IDO1 biosynthesis and
was found to be markedly suppressed by the vaccine (Figure 10, Table 1)(Orabona,
2006). This finding suggests a portion of the tolerogenic function of the CTB-INS
vaccine may be centered on promotion as well as prevention of IDO1 down-regulation.
Additionally, dendritic cell generated dopamine (DA) was shown to interact with the
dopamine related protein 5 (DAR5) to produce the pro-inflammatory cytokine IL-23 in
response to LPS stimulation thereby enhancing Th17 pro-inflammatory responses (Prado
et al., 2012). Ingenuity Pathway analysis indicated that CTB-INS vaccination may downregulate DC dopamine production through increased activation of the dopamine
degradation pathway (Figure 6B).
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Strengthening the opportunity for clinical testing in patients, our data showed that
CTB-INS did not interfere with monocyte differentiation into DCs. This result was
indicated by disappearance of the monocyte CD14+ marker following incubation with the
vaccine (Figure 11). In addition, dendritic cell expression of HLA-DR markers remained
unaffected. Dendritic Cell maturation markers such as CD86 and CD83 are synthesized at
much lower levels than normal in vaccine inoculated DCs confirming their regulatory
role in vaccine induced DC tolerogenesis. Showing their potential linkage, downregulation of co-stimulatory factors CD86 and CD83 in vaccinated DCs occurs
simultaneously with IDO1 up-regulation. As shown in Figure 12, knocking out IDO1
with siRNA results in increased expression of CD83 and CD86 suggesting IDO is
required for CTB-INS suppression of maturation and activation. Taken together, the data
support further consideration of CTB-INS for development as a safe and effective
immunosuppressive therapeutic strategy for prevention and reversal of tissue-specific
autoimmunity.

Conclusions
Our experimental data suggest CTB-INS vaccine-induced IDO1 biosynthesis is a likely
mechanism for safe and effective immune suppression of DC maturation leading to the
induction of durable peripheral tolerance. The mechanism for DC mediated tolerance
may occur through starvation of the DC for essential amino acids by depletion of cellular
tryptophan levels, the production of kynurenines known to be toxic to pro-inflammatory
T cells and the induction of regulatory T cells. Understanding how CTB-INS modulates
IDO1 activity in human dendritic cells will facilitate the improvement of vaccine efficacy
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and safety, moving this effective immunosuppressive strategy closer to clinical
applications for prevention of T1D.
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Abstract
A chimeric protein vaccine composed of the cholera toxin B subunit fused to
proinsulin (CTB-INS) was shown to suppress type 1 diabetes onset in NOD mice and
upregulate biosynthesis of the tryptophan catabolic enzyme indoleamine 2, 3dioxygenase (IDO1) in human dendritic cells (DCs). Here we demonstrate siRNA
inhibition of the NF-κB-inducing kinase (NIK) suppresses vaccine-induced IDO1
biosynthesis as well as IKKα phosphorylation. Chromatin immunoprecipitation (ChIP)
analysis of CTB-INS inoculated DCs showed that RelB bound to NF-κB consensus
sequences in the IDO1 promoter, suggesting vaccine stimulation of the non-canonical
NF-κB pathway activates IDO1 expression in vivo. The addition of Tumor Necrosis
Factor Associated Factors (TRAF) TRAF 2, 3 and TRAF6 blocking peptides to vaccine
inoculated DCs was shown to inhibit IDO1 biosynthesis. This experimental outcome
suggests vaccine activation of the TNFR super-family receptor pathway leads to
upregulation of IDO1 biosynthesis in CTB-INS inoculated dendritic cells. Together, our
experimental data suggest the CTB-INS vaccine uses a TNFR-dependent signaling
pathway of the non-canonical NF-κB signaling pathway resulting in suppression of
dendritic cell mediated type 1 diabetes autoimmunity.

Introduction
Type 1 diabetes (T1D) is a well-studied prototypic tissue specific autoimmune
disease resulting from auto-reactive lymphocyte destruction of the pancreatic islet
insulin-producing β-cells (Eisenbarth, 1986; Tisch & McDevitt, 1996). The progressive
loss of islet β-cell function leads to insulin deficiency and high blood glucose levels
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(hyperglycemia). Increased levels of cellular oxidative stress and chronic inflammation
generated by hyperglycemia leads to neural and circulatory complications that result in an
early mortality from amputation, loss of kidney function, blindness, heart attack, and
stroke (Forbes & Cooper, 2013; Melendez-Ramirez, Richards, & Cefalu, 2010).
Due to the high cost and extended duration of palliative patient care, there is an
urgent need for therapeutics that can safely deliver specific effective therapy that protects
against the onset and reverses the progression of tissue specific autoimmunity. Dendritic
cells, which are considered the most prominent subset of professional antigen presenting
cells (APC), have been implicated in the initiation of diabetes related islet β-cell
destruction (Allen et al., 2009; Ganguly, Haak, Sisirak, & Reizis, 2013; J. Mbongue,
Nicholas, Firek, & Langridge, 2014). Effective immunological suppression strategies
include chimeric vaccines that link immuno-stimulatory molecules (adjuvants) with
autoantigens to enhance vaccine efficacy (Aspord & Thivolet, 2002; Bergerot et al.,
1997; Ploix et al., 1999). Prominent among the adjuvants used is the cholera toxin Bsubunit (CTB) (Odumosu, Nicholas, Yano, & Langridge, 2010). C-terminal linkage of
CTB to the diabetes autoantigen proinsulin (CTB-INS), generated a fusion protein shown
to protect against T1D onset (Ploix et al., 1999). Oral immunization experiments
showed that feeding small amounts (2–20µg) of CTB-INS vaccine protein alone or in
recombinant plant tissues effectively suppressed β-cell destruction and clinical diabetes in
adult non-obese diabetic (NOD) mice (Aspord & Thivolet, 2002; Bergerot et al., 1997;
Denes et al., 2005).
Proteomic analysis of human dendritic cells inoculated with CTB-INS revealed
strong up-regulation of the tryptophan catabolic enzyme indoleamine 2, 3-dioxygenase
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(IDO1) (J. C. Mbongue et al., 2015). Previous observations showed that CD40 ligand
(CD40L) induced IDO1 biosynthesis in human DCs through activation of the noncanonical NF-κB signaling pathway (Tas et al., 2007). Thus, we assessed the requirement
for NF-κB activation in vaccine up-regulation of IDO1 using ACHP and DHMEQ,
pharmacological inhibitors of NF-κB (J. C. Mbongue et al., 2015). While these
experiments revealed vaccine stimulation of NF-κB was essential to activate IDO1
biosynthesis, the relative contributions of canonical and non-canonical NF-κB pathways
required for CTB-INS induction of IDO1 biosynthesis remained undetermined.
The NF-κB family in mammals is composed of five members, including c-Rel,
RelA also known as p65, NF-κB1 known as p50, RelB, and NF-κB2 known as p52.
These NF-κB family members form a variety of dimeric complexes capable of transactivating numerous target genes through binding to the κB enhancer (Sun, 2011). The
NF-κB subunit proteins are normally found inactive in the cell cytoplasm due to binding
by a family of inhibitors that include IκBa and several additional related ankyrin repeatcontaining proteins (Sun, 2011; Sun & Ley, 2008).
Due to the diversity of NF-κB functions, its activity is under tight control at
multiple levels by positive and negative regulatory elements. Under resting conditions,
NF-κB dimers are bound to inhibitory IκB proteins that retain NF-κB complexes in the
cytoplasm. In the canonical signaling pathway, the degradation of IκB inhibitor proteins
is initiated through stimulus-induced phosphorylation by IκB kinase (IKK), a molecular
complex consisting of two catalytically active kinases, IKKα and IKKβ, and their
regulatory subunit IKKγ (NEMO). Phosphorylation of IκB proteins target them for
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ubiquitination and proteasome degradation, releasing the NF-κB RelA (p65) and p50
protein dimers for translocation into the nucleus.
The non-canonical NF-κB signaling pathway was discovered during analysis of
non-canonical p100 subunit processing (Sun, 2011; Xiao, Fong, & Sun, 2004). In
addition to serving as a precursor of the functional p52 subunit, p100 was shown to
function like an IκB inhibitor molecule, preferentially inhibiting RelB nuclear
translocation (Solan, Miyoshi, Carmona, Bren, & Paya, 2002; Sun, 2011). Partial
proteasome processing of p100 serves to generate p52 and to induce nuclear translocation
of the RelB/p52 heterodimer as RelB binds to DNA with p52. The p52 subunit is actively
generated predominantly in specific immune cell types including B-cells and dendritic
cells, leading to the idea that p100 processing might be a signal-regulated event. Indeed
the NF-κB-inducing kinase (NIK) is required for p100 processing and is required for in
vivo p100 processing in splenocytes (Xiao et al., 2004; Xiao, Harhaj, & Sun, 2001). The
first component of the non-canonical signaling pathway to be identified was NIK, a
MAP-kinase kinase kinase (MAP3K) member originally implicated in NF-κB activation
by the TNF receptor (TNFR) pathway (Malinin, Boldin, Kovalenko, & Wallach, 1997).
To date, all of the non-canonical NF-κB inducers identified are known to signal through
NIK (Coope et al., 2002; Manches, Fernandez, Plumas, Chaperot, & Bhardwaj, 2012; Tas
et al., 2007).
Here we focus on identification of non-canonical NF-κB signaling pathway contributions
to CTB-INS vaccine induction of IDO1 in human dendritic cells as a prerequisite for
application of chimeric vaccine immune suppression strategies in the clinic.
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Materials and Methods
Construction of a Bacterial Expression Vector Containing the Cholera Toxin B
Subunit – Proinsulin Gene
A DNA sequence encoding 258bp of the human proinsulin gene (INS M12913.1)
was linked to the carboxyl-terminus of a DNA fragment (309bp) encoding the cholera
toxin B subunit gene (CTB U25679.1) to generate the fusion gene CTB-INS according to
a previously used protocol (J. C. Mbongue et al., 2015)(Figure 13).
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Figure 13. CTB-INS fusion protein was expressed from the E.coli pRSET A
expression vector and purified using Ni-NTA agarose with the indicated imidazole
concentration in the wash and elution steps. Panel (A) is a plasmid map of the E. coli
expression vector pRSET A (Invitrogen, Carlsbad, CA), carrying the CTB-INS fusion
gene. Panel (B) show the SDS-PAGE. Proteins were visualized by Coomassie staining.
Lane NI: non-induced E. coli (BL21) cell; I: induced E. coli cell; M: protein size marker;
CL: cell lysate; FT: flow-through; W: wash; E: elution. Panel (C) Western blot detection
of recombinant CTB-INS fusion protein identified with anti-CTB primary antibody. The
arrow indicates the purified CTB-INS proteins. Panel (D) shows the predicted CTB-INS
protein structure using its protein sequence generated by the RaptorX server.

126

Expression and Purification of CTB-INS Fusion Protein in E. coli
The E. coli strain BL21 was transformed with pRSET-CTB-INS as previously
described (J. C. Mbongue et al., 2015).

Ethics
Ex vivo experiments on monocyte-derived DCs were performed, with aphaeresis
blood provided by the Life Stream Blood Bank (San Bernardino, CA). These experiments
were approved by the Loma Linda University Adventist Health Sciences Center
Institutional Review Board and blood donor written consent. Blood donor information
was anonymized and de-identified prior to the study

Isolation and Culture of Monocyte - derived Dendritic Cells from Human Peripheral
Blood
Monocyte-derived dendritic cells (MoDCs) were prepared from freshly collected
human peripheral blood cells isolated from aphaeresis filter cones obtained from the
LifeStream blood bank (San Bernardino, CA). The blood was incubated with a red blood
cell lysis buffer (3.0 mL Lysis Buffer/ mL of blood) containing 8.3g/L NH4Cl, 1g/L
KHCO3, and 1.8 mL 5% EDTA (Boston Bioproducts), and centrifuged for 5 minutes at
1,500 rpm at 4°C in a Beckman Coulter Allegra X-15R centrifuge, equipped with a
SX4750 rotor. After a total of 3 washes in PBS to remove cellular debris and hemoglobin
CD14+ monocytes were obtained from the total lymphocyte fraction by incubation with
anti-CD14 antibodies bound to magnetic beads for 15 minutes at 4°C (Miltenyi Biotech,
Auburn, CA). The monocytes were separated from other immune cells by binding to a
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magnetic MACS column followed by elution of all other leucocytes (Miltenyi Biotech,
Auburn, CA). The monocytes were eluted from the column and cultured at a
concentration of 2-9 x 106 cells/well in 6-well non-pyrogenic polystyrene culture plates in
RPMI 1640 culture medium (Mediatech Inc. Manassas, VA, USA), supplemented with
10% FBS, 1 mM glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin, 50 ng/ml
human recombinant GMCSF, and 10 ng/ml human recombinant IL-4 (ProSpec-Tany), at
37°C in a humidified atmosphere of 5% CO2 (Preprotech, Rocky Hill, NJ). The monocyte
cell culture was fed at 2-day intervals by gentle replacement of 50% of the medium with
fresh pre-warmed culture medium. The cells were cultured for a total of 6 days to allow
monocyte differentiation into DCs prior to vaccine treatment. The cells were monitored
by phase contrast microscopy to assess dendrite formation, a marker indicating DC
differentiation.

IDO1 Protein Synthesis in Vaccinated Dendritic Cells
Approximately 2-9 x 106 monocyte-derived DCs generated from each of several
subjects were inoculated with CTB-INS (0.1, 0.5, 1.0, 2.5, 5.0 and 10 µg/ml), 500 ng/ml
of CD40L (Immunex, Seattle, WA), 500 ng/ml of TRAF 2,3 binding peptide (Proteintech
Group, San Diego, CA) and 500 ng/ml of TRAF 6 binding peptide (Proteintech Group).
The vaccinated DCs were incubated for 6, 12, 24, 48 or 96 hours and lysed in buffer C
(20 mM HEPES, 0.42 M KCl, 26% Glycerol, 0.1 mM EDTA, 5 mM MgCl2, 0.2% NP40,
37ºC) containing a tablet of complete protease inhibitor (Roche, Basel, Switzerland)
according to the manufacturer instructions. At least 50 µg of protein isolated from the
total DC lysate was separated by electrophoresis on a 12% polyacrylamide gel (SDS-
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PAGE). After transfer of the separated proteins to polyvinylidene difluoride (PVDF)
membranes (Millipore, Temecula, CA), the presence of IDO1 protein (NP_002155.1)
was detected by incubation of the blot for 12 hours at 4o C with an anti-IDO1 rabbit
monoclonal primary antibody (Cat. 04-1056, clone EPR1230Y) (Millipore, Temecula,
CA). For signal detection, the blot was washed 3 times with PBST (1X PBS, 0.02%
tween 20, pH 7.4) and incubated for 2 hours at room temperature in the presence of a
monoclonal anti-rabbit IgG γ-chain specific alkaline phosphatase conjugated secondary
antibody (Cat. A-2556, clone RG-96) (Sigma-Aldrich). The immunoblots were washed 3
times in PBST and incubated in 200 µL of Novex® AP chemiluminescent substrate
(Invitrogen™) for 5 minutes prior to exposure to x-ray film (Kodak X-Omat) for 3
minutes. The IDO signal intensity was quantified via Image J software v. 1.48h. (Image
J, NIH).

Small Interfering RNA (siRNA) Transfection
No pharmacological inhibitors for IKKα exist that selectively block the noncanonical pathway of NF-κB activation (Karin, Yamamoto, & Wang, 2004; Tas et al.,
2007). Here we used siRNA to specifically target this pathway. To define the regulatory
effect of the NF-κB pathway on CTB-INS-induced IDO expression, human NIK-small
interfering RNA (NIK siRNA, sc-36065) and non-targeting siRNA (Control siRNA
Fluorescein conjugate, sc-36869) were purchased from Santa Cruz Biotechnology (Santa
Cruz, Delaware, CA, USA). Monocytes were cultured in six-well plates for 4 days with
50 ng/ml of hGM-CSF and 10 ng/ml of IL-4 for differentiate the mature DCs. siRNAs
were transfected into DC cells using Lipofectamine® RNAiMAX reagent (Invitrogen,
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Carlsbad, CA, USA) according to the manufacturer’s protocol. Three microliters of 10
μM siRNA was mixture in 150 μl of Opti-MEN (Gibco-Life Technologies, Paisley,UK),
while 9 μl of Lipofectamine® RNAiMAX reagent was incubated in 150 μl of Opti-MEN
at room temperature for 5 min. Then the diluted siRNA and Lipofectamine® RNAiMAX
reagent were incubated for a further 20 min at room temperature for complex formation.
The complexes were added to wells. The final siRNA concentration was 25 pmol. DC
continued to be incubated at 37 °C in 5% humidified CO2 for 48 h which was sufficient to
significantly knock down the target protein levels. Expression of IDO1 was induced by 5
μg of CTB-INS for 24h after siRNA transfection. To evaluate transfection efficiency,
FITC-labeled control RNA was substituted for siRNA. After 24 hours, incubation, the
transfected DCs were analyzed by fluorescence microscopy for intracellular FITC
content. To confirm IKKα phosphorylation, DCs were treated with 10µg/ml of CTB-INS
for 6hrs after transfection and lysed in 100 µL buffer C/well containing phosphatase
inhibitors (50 mM Sodium-beta-glycerophosphate, 1mM Sodium fluoride, 1 mM
Sodium-ortho-vanadate). Western blot analysis with Anti-IKK alpha (phospho
S176+S180) (Abcam 1:1000) and anti-rabbit IgG whole molecule conjugated AP
(Sigma-Aldrich 1:1000) was performed prior to band detection on x-ray film (Kodak XOmat) of IKKα.expression.

Total RNA Preparation and Reverse Transcription Polymerase Chain Reaction (RTPCR)
Total RNA from 1 Х 106 DC was prepared using Trizol (Invitrogen, Carlsbad,
CA, USA) and complementary DNA was synthesized from 2 μg total RNA with oligo

130

(dT) primer in a 20 μl reaction volumn according to the manufacturer’s recommendations
(Thermo Fisher Scientific Inc, Waltham, MA, USA). Polymerase chain reaction (PCR)
amplification was performed at 95 °C for 1m, 58 °C for 1m, 72 °C for 30s, and PCR was
done for 35 cycles. The primers used in this study were NIK (h)-PR (sc-36065-PR, Santa
Cruze), product size 537 bp; and β-actin forward, 5’-GCA TTG CTT TCG TGT AAA
TTA TGT-3’ β-actin reverse, 5’-ACC AAA AGC CTT CAT ACA TCT CA-3’, product
size 211 bps. The PCR products were size-separated on 1.5% agarose gels and visualized
by Et-Br DNA gel staining.

ChIP Analysis of CTB-INS Induction of NF-κB Activation in Vivo
A chromatin immunoprecipitation (ChIP) assay was performed to identify the
specific binding sequences in the IDO1 promoter region for the non-canonical NF-κB
subunits RelB protein using a MAGnifyTM Chromatin Immunoprecipitation System
(Invitrogen) according to the manufacturer’s instructions. 3-8 x 106 Human dendritic cells
were left unstimulated or were stimulated with CTB-INS for 3h, after which DC cells
were harvested and washed with 1ХPBS and were fixed in formaldehyde (Sigma, St
Louis, MO, USA) to a final concentration of 1%. After 10 min, 1.25M glycine was added
to stop crosslinking reaction. After centrifugation, cells were lysed for 5 min in Lysis
buffer supplemented with protease inhibitors. Chromatin was sheared by sonication (5 Х
12s at one-fifth of the maximum potency) with a Sonic 60 Dismembrator (Fisher
Scientific, Sunnyvale, CA, USA), centrifuged to pellet debris, and diluted in Dilution
Buffer which was recommend in manufacturer’s instructions. Fragmented chromatin was
immunopreciated with a ChIP-grade antibody against RelB (GeneTex, Irvine, CA, USA)
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which was coupled with Dynabeads ®, at 4 °C overnight. Immune complexes were
washed with IP Buffer 1 and 2 in the DynaMagTM-PCR Magnet. For reversing the
crosslinking, Reverse Crosslinking Buffer with proteinase K was added both input
control (fragmented chromatin without immunoprecipitation) and immune complexes and
incubate at 55 °C for 15 min. The DNA was purified with DNA Purification Magnetic
Beads and buffers provided in the kit according to the manufacturer’s instructions. The
immunoprecipitated DNA was used in each real-time PCR assay using primers specific
for indicated regions of the DNA. The primers were designed using Primer Express 2.0
software (PE Applied Biosystems, USA) under default parameters. The primers that
were used are as follows: 5’-CGT TAA TGG TGA ATT CAG TGA TG-3’ (2732 F1)
and: 5’-TGC AGA GGG ACC TTC ATT CAA G-3’ (2732 R1), 5’-GGT AGA GAT
GTT CCT CAG GCA G-3’ (2961 F2) and 5’-CTC TAT GGC CTC CTA CAT CTG-3’
(2961 R2), 5’-TGA GTT CTG GCT TTC AGG AG-3’ (3072 F3) and 5’-GAT CTT GTC
TTC ATT CAC CTT G-3’ (3072 R3). Real-time PCR amplification reactions were
performed using SYBR Green detection chemistry and run as triplicate samples on 96well plates using the CFX 96TM Real-Time PCR Detection System (Bio-Rad). The PCR
reactions were prepared in a total volume of 25 μl containing: 5 μl of Chip or input
template DNA, 2 μl of each amplification primer (final concentration 50 nM), and 12.5 μl
of 2Х iQ SYBR Green Supermix (Bio-Rad). The cycling conditions were set as follows:
an initial denaturation step of 95 °C for 10 min to activate the iTaq DNA polymerase,
followed by 40 cycles of denaturation at 95 °C for 15 s, and annealing at 60 °C for 1 min.
The amplification process was followed by a melting curve analysis, ranging from 65 °C
to 95 °C, with temperature increasing at steps of 2 °C every 1 min. Baseline and
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threshold cycles (Ct), were automatically determined using the Bio-Rad CFX Manager
2.1. The samples were electrophoresed on a 1.5% (w/v) agarose gel, and the banding
pattern observed under UV light. Two biological replicates for each sample were used for
real-time PCR analysis and three technical replicates were analyzed for each biological
replicate.

Blocking TNFR Activation of IDO1 Biosynthesis
Peptides containing the CD40 receptor TRAF2, 3 and TRAF6 binding sites were
linked to the TAT47–57 cell penetrating peptide. The sequences for the CD40–TRAF2, 3
and the CD40–TRAF6 blocking peptides were NH2NTAAPVQETLHGYGRKKRRQRRR-OH and NH2KQEPQEIDFPDD YGRKKRRQRRR-OH respectively. The TAT47–57 sequence is
underlined. Control peptides consisted of either TAT47–57 alone or TAT47–57 linked to a
scrambled peptide. The peptides were manufactured by Proteintech Group (San Diego,
CA) and were low in endotoxin and > 98% pure as measured by HPLC (Portillo, Greene,
Schwartz, Subauste, & Subauste, 2015; J. A. Portillo et al., 2014).

CTB-INS Amino Acid Sequence Alignment with TNF Receptor Family Members
The protein amino acid sequence of CTB-INS (FASTA sequenceMIKLKFGVFFTVLLSSAYAHGTPQNITDLCAEYHNTQIYTLNDKIFSYTESLAGKR
EMAIITFKNGAIFQVEVPGSQHIDSQKKAIERMKDTLRIAYLTEAKVEKLCVWNN
KTPHAIAAISMANGPGPFVNQHLCGSHLVEALYLVCGERGFFYTPKTRREAEDL
QVGQVELGGGPGAGSLQPLALEGSLQKRGIVEQCCTSICSLYQLENYCNSEKDEL
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), was aligned with the following tumor necrosis factor (TNF) superfamily member
ligands: CD40L (Accession: NP_000065.1), TNFR14 (Accession: NP_003798.2),
RANKL (Accession: NP_003692.1), and BAFF (Accession: NP_006564.1) using the TCoffee server (http://tcoffee.crg.cat)(Notredame, Higgins, & Heringa, 2000). The protein
alignment graphics were constructed using Jalview software v1.6 (Waterhouse, Procter,
Martin, Clamp, & Barton, 2009).

Results
IDO1 Expression Following CTB-INS Incubation
Concentrations of 0.1-10 µg/ml CTB-INS were used to assess the minimal
concentration of CTB-INS needed to allow detection of IDO1 in monocyte-derived DCs.
Expression of IDO1 induced by CTB-INS occurred at concentrations as low as 0.5µg/ml
of CTB-INS (Figure 14A) Monocyte-derived DCs were incubated with CTB-INS for 6 to
96 hours with the medium replaced at 2 day intervals. The levels of IDO1 in vaccine
inoculated DCs increased continuously for 96 hours following vaccination (Figure 14B).
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Figure 14. IDO1 Expression with varying concentrations of CTB-INS and incubation times
and conditions. In panel (A) varying concentrations of CTB-INS from 0.1 to 10 µg/ml were
used to assess the minimal concentration of CTB-INS needed to cause detection of IDO1
in monocyte-derived DCs. In Panel (B) monocyte-derived DCs were incubated with CTBINS for 6 hrs to 96 hours with the medium changed every 2 days. IDO1 expression went
increasingly unabated for 96 hours. M: Marker. PC: Positive Control (IDO1 recombinant
protein) NC: Negative Control (Untreated).
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CTB-INS Stimulation of the Non-canonical NF-κB Pathway Induces IDO1
Synthesis in DCs
To assess non-canonical NF-κB pathway contributions to CTB-INS-induced
IDO1 expression we used siRNA technology to knock down the non-canonical pathwaydependent kinase NIK and the level of IDO1 expression in treated DCs measured. The
knockdown of NIK in CTB-INS stimulated DCs resulted in a significant reduction in
NIK mRNA levels (Figure 15A) and IDO1 protein expression as well as a decrease in
phosphorylated IKKα in comparison with non-specific siRNA-treated dendritic cells
(Figure 15B). This experimental result demonstrated that CTB-INS-induced IDO
expression in human DCs was dependent upon vaccine activation of the non-canonical
NF-κB pathway.
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Figure 15. The non-canonical NF-κB pathway is required for CTB-INS-induced IDO1
expression in monocyte-derived DCs. Panel (A) shows NIK mRNA levels in monocytederived DCs transfected with NIK-specific siRNA (siNIK) or negative control (siC)
examined by RT-PCR using NIK specific primers. The β-actin gene was used as an internal
standard in RT-PCR. This image is representative of two independent experiments. Panel
(B) graphic representation of NIK mRNA levels in CTB-INS vaccinated and unvaccinated
DCs. Panel (C) show the expression of IDO1 protein and phosphorylated IKKα in mDCs
transfected with NIK-specific siRNA (siNIK) or negative control (siC) examined by
Western blot analysis using anti-IDO1 as the primary antibody. This image is
representative of three independent experiments. Panel (D) shows graphic representation
of the cell viability of non-transfected or transfected with NIK-specific siRNA (siNIK) or
negative control (siC) in mDCs. Dendritic cell viability was measured by determination of
the percentage of vaccinated DCs negative for annexin V and propidium iodide. NT means
non-siRNA CTB-INS transfected DCs, and – or + means without CTB-proINS and with
CTB-INS. Samples were assayed in triplicates and the results represent the mean ± SD of
three independent experiments p=0.002. Statistical analysis was performed using one way
analysis of variance (ANOVA).
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CTB-INS Leads to Non-Canonical NF-κB RelB Translocation to Drive IDO1
Expression in DCs in vivo
The IDO1 promoter region was shown to contain three partial RelB/p52 binding
sites (AGGAGACACA, GGGAGACAGA, and AGGAGAAAGA), with a consensus
non-canonical binding sequence PuGGAGApyTTPu located close to position -2000
(Figure 16A), (Bonizzi & Karin, 2004; Manches et al., 2012; Puccetti & Grohmann,
2007). To demonstrate direct binding of RelB/p52 to the IDO1 promoter, we performed a
ChIP analysis experiment using RelB binding to pull-down the IDO1 promoter (Figure
16B). Immunoprecipitation of RelB induced by CTB-INS showed binding to all three
IDO1 non-canonical binding sequences with increased binding at the GGGAGACAGA
promoter sequence (Figure 16B,C).
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Figure 16. ChIP analysis showing vaccine stimulation of NF-κB RelB binding to the human
dendritic cell IDO1 promoter region in vivo. Panel (A) shows the sequence of three partial
non-canonical NF-κB RelB binding sites in the IDO1 promoter (bold nucleotides). The
arrows indicate the primer sequences for detection of the three RelB binding sites. Panel
(B) shows the PCR products after chromatin immunoprecipitation (ChIP). Immature
human DCs were stimulated with the CTB-INS fusion protein vaccine for 0 (-) or 6 hr (+).
Protein-DNA complexes were cross-linked, the DNA sheared and RelB genomic DNA
complexes immunoprecipitated with RelB monoclonal antibody. After purification of the
DNA, Real-time PCR was performed using primers flanking the three consensus NF-κB
RelB binding sites in the human IDO1 promoter region shown in panel A. The Input control
consists of PCR amplification of the IDO1 promoter obtained from total genomic DNA
prior to immunoprecipitation. Lane M: DNA fragment size marker, Lanes 1, 2, 3: show the
products of PCR amplification with primer sets detecting the three consensus RelB binding
sites in the vaccinated human IDO1 promoter region (white arrows). Panel (C)
Quantification of immunoprecipitation was performed for three experiments, by
normalizing the intensity of each immunoprecipitated band to its input.
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Vaccine Stimulation of the TNFR Signaling Pathway Induces IDO1 Biosynthesis in
Human DCs
Control of NIK post-translational stability may be essential for non-canonical NFκB signaling modulation. Therefore, the control of NIK stability is one of the prime
questions for understanding regulation of the non-canonical NF-κB signaling pathway.
Mounting evidence suggests that TNF receptor-associated factors, TRAF2, TRAF3 and
TRAF 6, are critical molecules involved in negative regulation of NIK activity (Hostager
& Bishop, 2013; Song & Kang, 2010; Vallabhapurapu et al., 2008). (Figure 17)
Pharmacological inactivation of these proteins or their deletion also allows for basal NIK
accumulation in the absence of ligand (Elgueta et al., 2009; Portillo et al., 2015; J. A.
Portillo et al., 2014; Sun, 2010, 2011; Xiao et al., 2004; Xiao et al., 2001).
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Figure 17. Activation of the non-canonical NF-κB pathway. In the basal inactive state
(left), the TRAF-cIAP complex catalyzes ubiquitination of NIK, leading to constitutive
NIK degradation in the proteasome leaving p100-containing RelB complexes isolated in
the cytoplasm. During activation (right), the TRAF-cIAP complex is recruited to the CD40
receptor. Upon ligand binding, TRAF2-mediated, ubiquitination of cIAP1/2 switches its
ubiquitin ligase activity from NIK to TRAF3. The resultant TRAF3 degradation
destabilizes the TRAF-cIAP complex allowing accumulation of newly synthesized NIK.
Phosphorylated NIK then transfers a phosphate to IKKα. Now activated, IKKα
phosphorylates p100 leading to its partial proteosomal degradation releasing p52: RelB
heterodimers that translocate into the nucleus. Further, activated IKKα phosphorylates
NIK, destabilizing it thereby limiting downstream activation events.
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The engagement of CD40 by CD40L promotes clustering of CD40 inducing the
recruitment of adapter proteins known as TNFR-associated factors (TRAFs) to the
cytoplasmic domain of CD40 (Elgueta et al., 2009). Previous reports showed that cell
permeable peptides that include the TRAF2, 3 or TRAF6 binding site to CD40 are able to
block the CD40-TRAF signaling pathway (Chatzigeorgiou et al., 2014; Chatzigeorgioua
et al., 2014; Elgueta et al., 2009; Lutgens, 2012; Portillo et al., 2015; J. A. C. Portillo et
al., 2014; Vallabhapurapu et al., 2008). Inhibition of the TNFR pathway permits
examination of its role in induction of IDO1 in vaccinated dendritic cells. Therefore,
monocyte-derived DCs were incubated with peptides containing the amino acid sequence
of the TRAF2, 3 and the TRAF6 binding sites to CD40. The DCs were then stimulated
with CD40 ligand (CD154), and CTB-INS. The CD40-TRAF2, 3 and CD40-TRAF6
blocking peptides were shown to impair upregulation of IDO1 in response to CD154, and
CTB-INS treatment. The most impairment of IDO upregulation was detected when both
TRAF 2, 3 and TRAF 6 inhibitors were used in combination. (Figure 18)
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Figure 18. The TNFR-TRAF pathway is required for CTB-INS vaccine induction of IDO1
protein biosynthesis. In Panels (A,B,C) monocyte-derived DCs were inoculated with
blocking peptides containing the amino acid sequence of TRAF2, 3 or TRAF6 binding
sites of CD40 linked to the TAT47–57 membrane transport peptide. After blocking peptide
binding, the DCs were stimulated with 500ng/ml of CD40L (CD154), Immunex, Seattle,
WA), LPS (1µg/ml) and CTB-INS (10µg/ml). Both CD40-TRAF2, 3 and CD40-TRAF6
blocking peptides impaired upregulation of IDO1 in response to CD154, LPS and CTBINS. Each image is representative of two independent experiments. (D) Relative cell
viability of cells treated with CTB-INS in combination with TRAF 6BP and TRAF 2, 3
BP.
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CTB-INS as a Ligand for Members of the TNFR Superfamily
Members of the Tumor Necrosis Factor (TNF) receptor family have been shown
to stimulate DC maturation or modulate peripheral tolerance in autoimmunity by
upregulation of IDO1 (Coope et al., 2002; Ma & Clark, 2009; Tas et al., 2007). Both
CTB and LTB enterotoxin protein binding subunits were shown to stimulate antigen
presenting cell CD40 surface expression and DCs were found to upregulate IDO1
mediated immune suppression through activation of the NF-κB non-canonical signaling
pathway (Tas et al., 2007). Protein functional homology analysis (PROPSEARCHTM)
identified the probability of functional homology between CTB-INS and the TNF
subfamily of ligands to be >87%, (unpublished data). Based on the data in (Figure 18) we
hypothesize that CTB-INS interacts with TNF receptors to stimulate IDO1 synthesis in
vaccinated DCs. To test this hypothesis, we aligned CTB-INS protein amino acid
sequence with the following tumor necrosis factor (TNF) superfamily member ligands:
CD40L (Accession: NP_000065.1), TNFR14L (Accession: NP_003798.2), RANKL
(Accession: NP_003692.1), and BAFF (Accession: NP_006564.1) using the T-Coffee
server. We observed that the CTB-INS vaccine shares significant levels of amino
sequence homology with ligands of the TNFR superfamily (Figure 19).
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Figure 19: Comparison of the amino acid sequence of CTB-INS with ligands of the Tumor
Necrosis Factor Receptor (TNFR) superfamily (CD40L, TNF14, RANKL and BAFF). The
light-blue horizontal line corresponds to the amino acid sequence of CTB and the darkblue horizontal line denotes the amino acid sequence of proinsulin. The black boxes
highlight areas of greater functional binding homology among TNFR family members, in
which the red highlighted areas signify greater levels of amino acid homology and the
green areas, low to no detectable homology.
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Discussion
The mechanism of CTB-INS induction IDO1 biosynthesis was shown to be
dependent on the NF-κB signaling pathway (J. C. Mbongue et al., 2015). However, the
relative contributions of canonical and non-canonical branches of this pathway to IDO1
up regulation remain unknown. Earlier work by Tas and his colleagues showed that
CD40L was responsible for stimulation of IDO1 via the non-canonical pathway (Tas et
al., 2007), suggesting this pathway could play a significant role in CTB-INS induction of
IDO1 in human DCs. Based on NIK-dependent activation experiments, our data suggest
CTB-INS induces IDO1 in human monocyte-derived DCs via the non-canonical NF-κB
pathway. In addition, ChIP analysis experiments showed that NF-κB RelB-p52 dimers
bound to defined consensus sequences within the IDO1 promoter in vivo, suggesting the
non-canonical signaling pathway is active in vaccine induction of IDO1 in human DCs.
Blocking TRAF adaptor molecule functions was shown to inhibit IDO1 biosynthesis in
vaccinated DCs suggesting upregulation of IDO may occur through TNF receptor family
stimulation of the NF-κB non-canonical signal transduction pathway (Song & Kang,
2010). In the TNF-activated signal transduction pathway, NIK is known to interact with
TRAF2, and TRAF3 leading to non-canonical NF-κB activation (Vallabhapurapu et al.,
2008).
Induction of IDO1 depends on fusion of CTB to proinsulin (J. C. Mbongue et al.,
2015), suggesting that the vaccine may bind as a ligand to receptors responsible for NFκB non-canonical pathway activation of IDO1 expression. Several ligands of the Tumor
Necrosis Family Receptor (TNFR) superfamily were shown to activate the non-canonical
NF-κB pathway (Bishop, Moore, Xie, Stunz, & Kraus, 2007; Hsu et al., 1997; Morrison,
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Reiley, Zhang, & Sun, 2005; Novack et al., 2003; Tas et al., 2007; Theill, Boyle, &
Penninger, 2002). For suggestive evidence of a link between CTB-INS with TNFR, we
compared amino acid sequences of CTB-INS with those of four ligands of the TNFR
family to assess any type of functional homology. We found that several areas where the
vaccine could act as a TNFR ligand, represented by areas of greater amino acid
homology (Figure 19).
The association between the ligand and its potential receptor suggests that CTBINS receptor binding may involve specificity of the autoantigen for its receptor rather
than existing as a general mechanism for binding all CTB-autoantigen conjugates. Our
experimental data suggests that CTB-INS induces non-canonical NF-κB signaling which
is driven by TRAFs as TNFR signal mediators. Although, there is evidence that CTBINS elicits immunosuppressive effects through TNFRs, further experiments are needed to
determine the probability of CTB-INS binding to individual members of the TNFR
family.
The B-cell activating factor (BAFF) predominantly expressed in B cells, differs
from many other TNFR superfamily members in that it generally activates the noncanonical NF-κB signaling pathway with only weak induction of canonical NF-κB
pathway signaling (Claudio, Brown, Park, Wang, & Siebenlist, 2002; Morrison et al.,
2005). This unique feature of the BAFF receptor (BAFFR) is due primarily to its
possession of an atypical TRAF-binding sequence, which interacts with TRAF3 but not
with TRAF2 (Morrison et al., 2005). The BAFFR-mediated induction of p100 processing
to p52 contributes to the survival of transitional and mature B cells, likely through
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induction of anti-apoptotic genes like bcl-2 and bcl-x (Claudio et al., 2002; Morrison et
al., 2005).
The CD40 molecule is a TNFR member expressed on a variety of cell types,
including B cells, dendritic cells, monocytes, endothelial epithelial cells, and neurons
(Bishop & Hostager, 2003; Ma & Clark, 2009). Activated T cells primarily express the
ligand of CD40, alternatively referred to as CD40L or (CD154). In the immune system, a
major function of CD40 signaling is to regulate B-cell activation and differentiation
events, including proliferation and survival of activated B cells, germinal center
formation, and antibody isotype switching. Another major function of CD40 is to mediate
dendritic cell maturation and antigen presentation. Unlike BAFFR, CD40 elicits strong
signals that target both the canonical and non-canonical NF-κB pathways (Ma & Clark,
2009; Tas et al., 2007). Upon ligation by CD40L, CD40 interacts via two different
TRAF-binding motifs that include TRAF1, 2, 3, 5, and 6, and this interaction leads to
proteolysis of both TRAF2 and TRAF3 (Bishop et al., 2007; Harnett, 2004). As indicated
above, the degradation of TRAF2 and TRAF3 represent an important step in the
activation of the non-canonical NF-κB signaling pathway (Sun, 2010, 2011; Sun & Ley,
2008).
The herpesvirus entry mediator (HVEM) or tumor necrosis factor receptor
superfamily member 14 (TNFRSF-14) is a protein originally known as herpesvirus entry
mediator A (HveA). Both HveB and HveC are structurally unrelated proteins of the
immunoglobulin superfamily (Montgomery, Warner, Lum, & Spear, 1996). HvA is also
known as Cluster of Differentiation CD270 (Hsu et al., 1997). Moreover it is also
referred to as ATAR (another TRAF-associated receptor). Interactions between TNFRSF-
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14 and TRAF2 were shown to activate the non-canonical NF-κB signaling pathway (Hsu
et al., 1997).
The Receptor Activator of Nuclear Factor κ B (RANK) is best known for its role
in osteoclastogenesis (Novack et al., 2003; Sun, 2011). However, it also regulates
important immune functions that include dendritic cell survival and lymphoid
organogenesis (Theill et al., 2002). RANK is expressed on osteoclast precursors,
dendritic cells, and activated B cells, and in general, RANK signaling was shown to
promote cell survival and differentiation. Analogous with CD40, the cytoplasmic domain
of RANK was shown to bind TRAF1, 2, 3, 5, and 6 and mediates activation of both
canonical and non-canonical NF-κB signaling pathways. Genetic evidence suggests an
essential role for RANK-stimulated activation of non-canonical NF-κB activation during
osteoclastogenesis and bone metabolism (Novack et al., 2003). The non-canonical NF-κB
has been closely linked to immune suppression (J. C. Mbongue et al., 2015; Pallotta et
al., 2011). Several ligands such as Glucocorticoid-induced tumor necrosis factor receptor
(GITR) on T cells and its natural ligand, GITRL, on accessory cells contribute to the
control of immune homeostasis. Grohmann et al. showed that reverse signaling through
GITRL after engagement by soluble GITR initiates the immunoregulatory pathway of
tryptophan catabolism in mouse plasmacytoid dendritic cells, by means of noncanonical
NF-κB–dependent induction of IDO1 (Grohmann et al., 2007). Additionally, CpG-rich
oligodeoxynucleotides activate the immune system, leading to innate and adaptive
immune responses that have been shown to promote tolerogenic responses in mouse
plasmacytoid dendritic cells in vivo and in an in vitro human DC model. Unveiling a
previously undescribed role for TRIF and TRAF6 proteins in Toll-like receptor 9 (TLR9)
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signaling, it was demonstrated that physical association of TLR9, TRIF and TRAF6 leads
to activation of non-canonical NF-κB signaling and the induction of IRF3- and TGF-βdependent immune-suppressive tryptophan catabolism (Volpi et al., 2013).
Understanding the link between vaccine activation of TNF receptor family
members and the activation of non-canonical NF-κB signaling is an important step in
elucidation of the mechanism underlying chimeric vaccine induction of immunological
tolerance in dendritic cells. Understanding the mechanism of chimeric vaccine
modulation of IDO1 induction and suppression of in human dendritic cell activation will
facilitate development of chimeric vaccine strategies for effective and safe therapy for
type 1 diabetes and a wide range of tissue specific autoimmune diseases.
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CHAPTER FOUR
CONCLUSIONS

Our laboratory previously demonstrated the phenomenon of suppression of
insulitis and autoimmune diabetes in NOD mice inoculated with CTB-INS (Arakawa,
Chong, & Langridge, 1998). However, the cellular and molecular mechanisms underlying
CTB-proinsulin – immune cell interactions involved in the suppression of disease
pathology are incompletely understood. Because dendritic cells are the dominant
population of antigen presenting cells involved in the induction of inflammatory and
autoreactive T cell morphogenesis, we investigated early effects of CTB-INS on human
immature dendritic cell activation and maturation in vitro and attempted to correlate these
results with findings from NOD mice diabetes onset studies. Our experiments suggest
that CTB when conjugated to insulin (CTB-INS) results in the suppression of dendritic
cell activation and maturation as determined by a failure of CTB-INS and to a limited
extent proinsulin alone to stimulate the upregulation of immature dendritic cell CD86 and
CD83 costimulatory factors. This observation was further confirmed when CTB-INS
stimulated DCs resulted in an increase in DC secretion of the anti-inflammatory cytokine
IL-10 (Odumosu et al., 2011). Previous observations show that CTB can greatly enhance
the immunogenicity of linked antigens (George-Chandy et al., 2001) by inducing DC upregulation of CD86 and CD83. Morphological changes which included enlargement of
immature dendritic cells, elongation of DC dendrites and increased migration of DCs into
draining lymph nodes observed in those studies was not monitored in the present study.
Earlier NOD mouse insulin inoculation experiments conducted by Bergerot et. al.,
demonstrated sustained prevention of diabetes onset, even when oral insulin treatment
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was initiated as late as 15 weeks after birth of the mice. In addition, the protective effect
against continued insulitis development was transferable to untreated NOD mice through
transfer of CD4+ T cells from CTB-INS inoculated animals (Bergerot et al., 1997) Our
recent finding that CTB-INS is active in the suppression of DC maturation provides a
possible explanation for CTB enhanced insulin mediated diabetes suppression observed
in NOD mice studies employing CTB-INS fusion protein produced in viruses, plants, and
silkworm larvae (Denes, Fodor, & Langridge, 2013; Meng, Wang, Shi, Jin, & Zhang,
2011).
In our experiments, CTB-INS stimulated iDCs produced significantly higher
levels of IL-10 than in CTB or proinsulin stimulated iDCs. However of interest, the
biosynthesis of IL-12/23p40 subunit was significantly inhibited (Odumosu et al., 2011).
This result is critical because induction of cognate naïve T helper cell (Th0)
morphogenesis into Th1 effector cells that secrete IFN-γ and IL-2 responsible for islet
inflammation and beta cell death is dependent on DC synthesis of IL-12 in addition to
expression of surface costimulatory molecules (Pulendran et al., 1999).
Additionally we demonstrate an essential requirement of the non-canonical NFκB pathway for regulatory functions in DCs, including effective IDO1 induction and
negative regulation of pro-inflammatory cytokine production. Selective canonical NF-κB
inhibition results in DCs that induce T cells with suppressive function via a noncanonical pathway-dependent mechanism. Our experimental data suggest the CTB-INS
vaccine stimulates TNFR superfamily activation of the non-canonical NF-κB signaling
pathway resulting in suppression of dendritic cell mediated type 1 diabetes autoimmunity.
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These findings in combination with our experiments demonstrating CTB-INS
induction of IDO1-role of which has been presented in detail- may be critical to
determine the probable cellular mechanisms underlying CTB-INS mediated immune
suppression of T1D. Future experiments incubating CTB linked autoantigens with naïve
DCs will reveal the capacity of CTB-INS to arrest the progression of type 1 diabetes once
hyperglycemia has become established. Establishment of CTB-INS mediated
immunological suppression of type 1 diabetes progression will help to determine whether
this form of interventional therapy in combination with anti-inflammatory cytokines can
prevent both the onset and the progression of diabetes once hyperglycemia has
developed. Once durable immunological suppression of diabetes progression has been
achieved, interventional therapy with insulin producing mesenchymal stem cells may
provide an effective, safe and durable cure for the present ravages of type 1 diabetes.
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